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ABSTRACT
Characterizing the Function of PAS kinase in Cellular Metabolism and
Neurodegenerative Disease
Jenny Adele Pape
Department of Microbiology and Molecular Biology, BYU
Doctor of Philosophy
PAS kinase 1 (Psk1) is a sensory protein kinase responsible for activating and
deactivating many pathways in the cell. Dysregulation of PAS kinase can lead to a variety of
diseases, ranging from obesity to cancer to neurodegenerative disease. Herein, we provide an indepth analysis of two known interacting partners of PAS kinase, Centromere binding factor 1
(Cbf1) and poly(A)- binding protein binding protein 1 (Pbp1). PAS kinase phosphorylates Cbf1
inhibiting its function and decreasing respiration in yeast. In agreement, CBF1-deficient exhibit
decreased respiration. Although the number of mitochondria is not altered by CBF1-deficiency, a
mitochondrial proteomics analysis revealed an altered mitochondrial composition. Through betagalactosidase assays and western blot, we showed direct transcriptional control of Atp3 (a
subunit of the mitochondrial F1-ATP synthase complex), and the yeast lipid genes Lac1 and
Lag1 by Cbf1. Furthermore, we confirmed the human homolog of Cbf1, USF1, as a substrate of
PAS kinase in vitro and provided the first evidence for the role of USF1 in respiration. Our
model suggests that PAS kinase decreases respiration through the inhibition of Cbf1, partitioning
glucose away from respiration and towards lipid synthesis. We expanded on the role of PAS
kinase in glucose regulation through a mouse study including wild-type and PAS kinase deficient
mice on either a normal chow or high-fat-high-sugar diet. Our results showed increased
respiration in PAS kinase deficient males only on a normal chow diet. PAS kinase-deficiency
was not shown to protect against weight gain when on a high-fat high-sugar diet, but it did
significantly protect from liver triglyceride accumulation. Interestingly, females were protected
from triglyceride accumulation regardless of genotype. This suggests that sex may be masking
the effects of PAS kinase.
The second identified substrate of PAS kinase discussed is Pbp1. The human homolog of
Pbp1 is ataxin-2, mutations in which are a known risk factor for amyotrophic lateral sclerosis
(ALS). As diet and sex have been shown to be important factors regarding PAS kinase function,
they also are strong contributing factors to ALS and are extensively reviewed herein. Pbp1 is
known to be sequestered by PAS kinase under glucose depravation, and it can sequester
additional proteins along with it to regulate different cellular pathways. To shed light on the
pathways affected by Pbp1, we performed a yeast two-hybrid assay and mass spectrometry,
identifying 32 novel interacting partners of Pbp1 (ataxin-2). We provide further analysis of the
direct binding partner Ptc6, measuring mitophagy, mitochondrial content, colocalization, and
respiration. This work elucidates novel molecular mechanisms behind the function of PAS
kinase and yields valuable insights into the role of PAS kinase in disease.
Keywords: PAS kinase, Cbf1, USF1, respiration, glucose allocation, ALS, neurodegenerative,
ataxin-2, Pbp1, stress granules, Ptc6, mitophagy
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CHAPTER 1: PAS kinase Works through its Substrates to Regulate Metabolism and
Neurodegenerative Disease
1.1 Introduction
A cells ability to appropriately sense and allocate nutrients in their environment is
essential to the health of the cell. Without proper maintenance, metabolic disease such as
diabetes, heart disease, and cancer may develop. Sensory protein kinases are key regulators of
metabolic processes, with the ability to sense nutrients in the environment and respond by
activating and deactivating many different pathways within the cell. By developing drugs that
target specific protein kinases, it may be possible to restore healthy cellular pathways that have
developed due to disease.

Figure 1.1 A model of PAS kinase activation and function [1].

The protein PAS (Per-Arnt-Sim) kinase is a nutrient sensory protein kinase that responds
to glucose and regulates its allocation throughout the cell. PAS kinase contains both a
serine/threonine catalytic kinase domain and a regulatory PAS (Per-ARNT-Sim) domain [2]. In
the model for PAS kinase regulation and function, the N-terminal of the PAS domain binds and
1

inhibits the serine/threonine c-terminal kinase domain in cis. To activate the kinase, it is
hypothesized that small metabolites bind to the PAS domain, releasing and thereby activating the
catalytic kinase domain (Figure 1.1) [3]. This suggests that PAS kinase may work to modulate
cellular growth based on nutrient availability.
PAS kinase is highly conserved between yeast, mice, and man. Initial studies in mice
revealed no significant differences in development, growth or reproduction between wild-type
(WT) and PAS kinase knockout (KO) mice. However, when placed on a high fat diet, PAS
kinase knockout mice exhibited weight gain (Figure 1.2), increased triglyceride accumulation,
glucose tolerance and insulin sensitivity comparable to their wild-type littermates. Each of these
levels were significantly elevated in the wild-type mice on a high fat diet. [4].

Figure 1.2 WT mice on a HFD gain significantly more weight than KO mice on a HFD [4].
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Despite its importance, little is known about the molecular mechanisms of PAS kinase
function including the substrates it acts on. Yeast two hybrid assays and co-purification were
performed to better understand the specific molecular pathways being utilized by PAS kinase.
These experiments revealed 93 putative binding partners of PAS kinase. Of these 93 partners, a
remarkable 73% appeared to have a human homolog, whereas only 20-30% of the yeast
proteome is reportedly conserved in humans [5]. This supports the evolutionary conservation of
PAS kinase and its critical role in regulating central metabolic pathways. One protein of the two
proteins that were collected from both the yeast two hybrid assay and co-purification was Pbp1.
Pbp1 is a largely uncharacterized a poly(A)-binding protein (Pab1)-binding protein associated
with stress granule formation. In-vitro kinase assays revealed PAS kinase dependent
phosphorylation of Pbp1 as well as PAS kinase dependent phosphorylation of Pbp1’s human
homolog, Ataxin-2. Pbp1 is the yeast homolog of human ataxin-2 (Figure 1.3) [6].

Figure 1.3 Evidence for direct phosphorylation of Pbp1 by PAS kinase [6].

In 2010, it was found that mutations in ataxin-2 significantly increased the risk for
amyotrophic lateral sclerosis (ALS) [10]. ALS is a neurodegenerative disorder that causes
muscle weakness, disability, and eventually fatal paralysis normally within 3-5 years of
diagnosis. The etiology of the disease is still unknown, with only about 10% of ALS cases being
3

familial, the rest being sporadic [7]. Riluzole is the only drug has been developed and shown to
have an impact on survival in ALS, yet it is still unclear how it works with ALS [8, 9]. Currently
the mainstay treatment for ALS is symptomatic management through multidisciplinary care,
such as respiratory management, counseling, pain management, and communication therapy
[10]. It therefore is imperative to identify and understand disease related genes to develop
effective treatment for ALS.
Ataxin-2 is thought to increase one’s risk for ALS through its association with TAR DNA
binding protein (TDP-43). [11]. TDP-43 has recently been identified as the major disease
causing protein in ALS [12]. TDP-43 positive ubiquinated neuronal cytoplasmic inclusions have
been found in the spinal motor neurons in 97% of all ALS cases [13]. It has been shown that
lowering ataxin-2 levels in both yeast and flies will protect against TDP-43 aggregation and
toxicity [11]. In TDP-43 transgenic mice, complete loss of ataxin-2 extended the survival of mice
by over 80% (Figure 1.4) [13].

Figure 1.4 Reducing the level of ataxin-2 extends lifespan in TDP-43 transgenic mice [13].

4

As mentioned above, PAS kinase directly phosphorylates and activates the yeast ataxin-2
homolog, Pbp1 [6, 14] . Under normal conditions, PAS kinase causes overexpression of Pbp1 or
ataxin-2 in yeast. However, PAS kinase deficiency decreases toxicity due to the inability to
overexpress Pbp1. In addition, PAS kinase decreases the amount of Pbp1 and ataxin-2
localization to stress granules. Pbp1 and PAS kinase were recently shown to be required for the
sequestration of the nutrient sensing TORC1 at stress granules in yeast and there is some
evidence for this conservation of function in mammalian cells (Figure 1.5) [15]. TORC1 is a
central regulator of cell growth and proliferation and is essential for cell survival. Together, these
results suggest that PAS kinase inhibition may reduce the activity and/or levels of ataxin-2, and
rescue TORC1 inhibition. PAS kinase could be an ideal target to lower levels of ataxin-2.

Figure 1.5 A model for PAS kinase dependent phosphorylation and activation of Pbp1/ataxin-2 which
leads to inhibition of TORC1 through its sequestration at stress granules [6].

1.2 Summary of research chapters
Chapter 2 outlines our efforts to characterize a novel substrate of PAS kinase,
Centromere binding factor 1 (Cbf1). We show that while PAS-kinase deficient yeast exhibit
increased respiration, Cbf1-deficient yeast exhibit decreased respiration. We identify ATP3, a
subunit of the mitochondrial F1-ATP synthase complex, as a contributing factor to the decrease
5

in respiration. We also discover a Cbf1 dependent regulation of Lac1 and Lag1, two genes
involved in the synthesis of ceramides in yeast. Finally, we also show that the human homolog of
Cbf1, Upstream transcription factor 1 (USF1), behaves similarly to Cbf1.
In Chapter 3 we provide further characterization of PAS kinase deficient mice. Typically,
male mice are used to study PAS kinase as they present with more intense phenotypes. However,
in our study we included both male and female mice, and while some phenotypes were similar,
we saw many unexpected differences. In addition, our mice were put on either a normal chow
(NC) diet or a high-fat high-sugar (HFHS) diet that more accurately reflects the Western Diet
found in today’s society. We show PAS kinase dependent changes in respiration via respiration,
western blot, ATP assays, and weight analysis. In addition, we provide an in-depth hepatic
triglyceride profiling that verifies PAS kinase deficiency can protect against triglyceride
accumulation.
Chapter 4 is a review paper discussing how diet and metabolic health influence ALS risk,
onset, progression, and survival time. In addition, we highlight various sex differences seen in
ALS. PAS kinase has been shown to regulation Ataxin-2, a risk factor for ALS. Due to the sexdependent changes reported in chapter 3, this review provides insight into how diet, metabolic
health, and sex may influence molecular pathways in ALS and helps to understand how to better
design experiments in ALS models in order to uncover novel phenotypes.
Chapter 5 is an unpublished study focused on identifying the interacting partners of Pbp1
as well as the characterization of an interacting partner, Ptc6, that regulates mitochondrial health
in the cell.

6
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CHAPTER 2: The Regulation of Cbf1 by PAS kinase is a Pivotal Control Point for
Lipogenesis vs. Respiration in Saccharomyces cerevisiae

The following chapter is taken from an article published in Genes, Genomics, and Genetics
Journal. All content and figures have been formatted for this dissertation but it is otherwise
unchanged.

2.1 Abstract
PAS kinase 1 (Psk1) is a key regulator of respiration in Saccharomyces cerevisiae.
Herein the molecular mechanisms of this regulation are explored through the characterization of
its substrate, Centromere binding factor 1 (Cbf1). CBF1-deficient yeast displayed a significant
decrease in cellular respiration, while PAS kinase-deficient yeast, or yeast harboring a Cbf1
phosphosite mutant (T211A) displayed a significant increase. Transmission electron micrographs
showed an increased number of mitochondria in PAS kinase-deficient yeast consistent with the
increase in respiration. Although the CBF1-deficient yeast did not appear to have an altered
number of mitochondria, a mitochondrial proteomics study revealed significant differences in the
mitochondrial composition of CBF1-deficient yeast including altered Atp3 levels, a subunit of
the mitochondrial F1-ATP synthase complex. Both beta-galactosidase reporter assays and
western blot analysis confirmed direct transcriptional control of ATP3 by Cbf1. In addition, we
confirmed the regulation of yeast lipid genes LAC1 and LAG1 by Cbf1. The human homolog of
Cbf1, Upstream transcription factor 1 (USF1), is also known to be involved in lipid biogenesis.
Herein, we provide the first evidence for a role of USF1 in respiration since it appeared to
complement Cbf1 in vivo as determined by respiration phenotypes. In addition, we confirmed
9

USF1 as a substrate of human PAS kinase (hPASK) in vitro. Combined, our data supports a
model in which Cbf1/USF1 functions to partition glucose towards respiration and away from
lipid biogenesis, while PAS kinase inhibits respiration in part through the inhibition of
Cbf1/USF1.
2.2 Introduction
Proper resource allocation is fundamental to the success of any system. In cellular
organisms, it is crucial to sense available nutrients and astutely allocate them among several
pathways including growth, storage and energy metabolism. If nutrients are not properly
allocated, e.g. when too many nutrients are diverted to one pathway, it comes at the expense of
another important pathway and often leads to diseases such as obesity, diabetes and cancer. One
of the mechanisms that cells have evolved to help coordinate resource allocation are nutrient
sensing protein kinases.
PAS kinase is a highly conserved sensory kinase with both a sensory PAS (Per-ARNTSim) domain and a serine/threonine kinase domain [1]. It is a key player in sensing and
allocating glucose in eukaryotic cells (reviewed in [2-8]). Additionally, PAS kinase is activated
both in yeast and mammalian cells under conditions that activate respiratory metabolism [9, 10].
This occurs in yeast when cells are grown on carbon sources other than glucose and in
mammalian cells under conditions of high glucose.
PAS kinase is not only activated by respiratory conditions, but is also implicated in
regulating respiratory metabolism itself. PAS kinase-deficient mice (PASK-/-) have a
hypermetabolic phenotype in that they consume more oxygen and give off more CO2 and heat
when placed on a high-fat diet [11]. In contrast, PASK-/- mice also accumulate significantly less
hepatic lipids when placed on the high-fat diet and PAS kinase knockdown or inhibition also
10

decreases triglyceride in hepatic cell lines. These data suggest that PAS kinase is allocating
glucose away from respiration towards lipid storage in wild type mice. However, the
mechanisms behind these phenotypes are largely unknown. We recently identified a novel
substrate of yeast PAS kinase 1 (Psk1), Centromere binding factor 1 (Cbf1), that could be an
important player in the mechanisms behind these phenotypes [12].
Cbf1 is a general transcription factor conserved from yeast to man [13-15]. Its human
homolog, Upstream transcription factor 1 (USF1), is a key regulator of genes involved in lipid
homeostasis and USF1 mutations are strongly correlated with hyperlipidemia [16-20]. In yeast,
transcriptome data suggests that Cbf1 regulates a wide variety of genes including those involved
in respiration and lipid biogenesis, as well as amino acid biosynthesis [15, 21, 22]. We recently
provided evidence for decreased respiration in CBF1-deficient yeast and for the PAS kinasedependent phosphorylation and inhibition of Cbf1 [12]. The altered respiration observed in yeast
lacking CBF1 or PAS kinase may be due to many effects within the cell such as 1) effects on
total mitochondrial mass or 2) electron transport chain expression or activity. Here we further
characterized the mechanisms behind PAS kinase and Cbf1 respiratory function in yeast.
Specifically, we report the differences observed in mitochondrial area between wild type, CBF1deficient and PAS kinase-deficient yeast and present the mitochondrial proteomes of these yeast.
In addition, we confirm the role of CBF1 in regulating the yeast lipid genes LAC1 and LAG1 and
provided evidence that they are downregulated by CBF1 under the same conditions that ATG3 is
upregulated. Evidence is also provided for USF1 being a conserved PAS kinase substrate
through in vitro kinase assays as well as yeast complementation assays. Combined, our data
supports a model in which Cbf1/USF1 partitions glucose towards respiration at the expense of
lipid biogenesis, while PAS kinase inhibits Cbf1/USF1 favoring lipid biogenesis.
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2.3 Materials and methods
2.3.1 Growth assays and vector construction
A list of strains, plasmids and primers used in this study are provided in Table 2.1. All
plasmids constructed for this study were made using standard polymerase chain reactions (PCR)
followed by restriction digests using enzymes from New England Biolabs [23]. Human USF1
was PCR amplified using primers 3456/3457 from plasmid pCMV6-USF1 (OriGene, SC
1227700). CBF1-deficient yeast acquire suppressors at a rapid rate. Therefore, all cultures were
streaked fresh from frozen and used as quickly as small colonies appeared.
Table 2.1 Strains, plasmids and primers used in this study
Strain

Background Genotype

Abbreviation a/α

Reference or source

JGY1

W303

his3, leu2, lys2, met15, trp1, ura3

WT

JGY4

W303

psk1::his3, psk2::kan-MX4, leu2, lys2,
met15, trp1, ura3

psk1psk2

a

David Stillman, University
of Utah
[9]

JGY43
BY4741
JGY1227 BY4741
JGY1244 BY4741
JGY1261 BY4741
JGY1348 BY4741
JGY1349 BY4741
JHG504 BL21DE3

a

his3-1, leu2-0, met15-0, ura3-0
cbf1::kan-MX4, his3-1, leu2-0, met15-0,
ura3-0
psk1::hph-MX4, psk2::nat-MX4, his3-1,
leu2-0, met15-0, ura3-0
psk1::hph-MX4, psk2::nat-MX4, cbf1::kanMX4, his3-1, leu2-0, met15-0, ura3-0
psk1::kan-MX4, his3-1, leu2-0, met15-0,
ura3-0
psk2::kan-MX4, his3-1, leu2-0, met15-0,
ura3-0

WT
cbf1

a
a

[51]
[51]

psk1psk2

a

This study

psk1psk2cbf1 a

This study

F- ompT hsdSB(rB-mB-) gal dcm (DE3)

BL21

Novagen

Yeast
Origin

Selection Reference or source

psk1

a

[51]

psk2

a

[51]

Plasmid

Gene

Description

Backbone

pJG121
pJG173
pJG210
pJG725
pJG858
pJG1009
pJG1025
pJG1031
pJG1232
pJG1233
pJG1246
pJG1314
pJG1315
pJG1316
pJG1317

EV
PSK2
UGP1
EV
PSK1
EV
IPP1
CBF1
USF1
USF1
USF1
LACZ
ATP3
COX4
HAP4

Empty pRS415 plasmid
pGAL1-10-PSK2-HIS/HA
Ugp1-HIS
pAdh-myc
pGAL1-10-PSK1-HIS/HA
pET15b with James Y2H MCS
IPP1 into pET15b (pJG1009)
CBF1 into pET15b
USF1 in pCMV
USF1 into pET15b
USF1 into pJG725
LACZ into pJG121
ATP3-LACZ
COX4-LACZ
HAP4-LACZ

pRS415
CEN
pRS426
2u
pHIS-parallel
pRS416
CEN
pRS426
2u
pET15b
pET15b
pET15b
pCMV6-XL5
pET15b
pRS415
CEN
pRS415
CEN
pRS415
CEN
pRS415
CEN
pRS415
CEN
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LEU
URA
AMP
URA
URA
AMP
AMP
AMP
AMP
AMP
URA
LEU
LEU
LEU
LEU

(Simons et al, 1987)
(Grose et al., 2007)
(Smith et al, 2007)
[12]
(DeMille et al., 2014)
[12]
[12]
[12]
OriGene
This study
This study
This study
This study
This study
This study

pJG1318
pJG1320
pJG1321
pJG1322
pJG1335
pJG1336

NDI1
QCR6
LAC1
LAG1
CBF1
CBF1

NDI1-LACZ
QCR6-LACZ
LAC1-LACZ
LAG1-LACZ
T211A-Cbf1 into pJG725
T212A-Cbf1 into pJG725

pRS415
pRS415
pRS415
pRS415
pRS416
pRS416

CEN
CEN
CEN
CEN
CEN
CEN

LEU
LEU
LEU
LEU
URA
URA

Primer

Sequence

JG3440
JG3441
JG3442
JG3443
JG3457
JG3458
JG3652
JG3683
JG3684
JG3669
JG3670
JG3671
JG3672
JG3673
JG3674
JG3675
JG3676
JG3679
JG3680
JG3741
JG3799
JG3800
JG3801
JG3802

GGCCTCGAGCATTTTCTGTCGCTCTTATGATCC
GGCAAGCTTTGTCCACATAGCTCTTGTTTATTGA
GGCCTCGAGCCTCTTGTCCATTATCTTCGGGA
GGCAAGCTTTGATGTCATGTTGTCGTTATTTCTTC
GGCCTCGAGGTTGCTGTCATTCTTGATGACG
CGAATTCATGAAGGGGCAGCAGAAAACAGCTG
GGCCTCGAGGTATAATGTACCTTTGTTCCCTACAC
GGCAAGCTTATGACCATGATTACGGATTCACTGG
GGCGGATCCTTTTTGACACCAGACCAACTGGTAATG
GGCAAGCTTTAGAAAAGTCTTTGCGGTCATGATTC
GGCCTCGAGTTTCATCAAGGACTAAAGTTTTCTTATG
GGCAAGCTTTGATACAATTCTTGACAACATGACTAC
GGCCTCGAGGGCAAGCTTGACCTTTACTTTCCTCTCTAAAAGCC
GGCAAGCTTTTCCAACATGCCCATTTTCTATTTC
GGCCTCGAGCGAACAGCACAAGACGCGTATCAC
GGCAAGCTTTAGTGAAAGCATTGTGCTTGTTATC
GGCCTCGAGGCGGATTCCAAAGGCGTCCTTC
GGCAAGCTTCTTCGATAGCATAGTGGTTTTTAG
GGCCTCGAGGACCGGCGCTACCCGGTTAAG
GGCAAGCTT GATGTAGGGCATTACTTCTTTGATG
GGAAGAAATGTTTATCACCAGATGGAGAACCAATGAGCGG
CCGCTCATTGGTTCTCCATCTGGTGATAAACATTTCTTCC
GTCGTATTATTGAGTCACCAGCTTTATTCCATGGCGGG
CCCGCCATGGAATAAAGCTGGTGACTCAATAATACGAC

This study
This study
This study
This study
This study
This study

2.3.2 In vitro kinase assays
Full-length HIS-tagged yeast Psk1 (pJG858), Psk2 (pJG173) and Ugp1 (pJG210) proteins
were purified from yeast (JGY4), while Cbf1 (pJG1031) and USF1 (pJG1233) proteins were
from BL21DE3 E. coli (JHG504) as previously described [24] using Ni-NTA (Qiagen,
Chatsworth, CA) chromotography. hPASK was expressed in Sf9 insect cells using the BAC-toBAC baculovirus expression system (GIBCO/BRL) as previously described (Rutter et al. 2001)
and purified using Ni-NTA (Qiagen, Chatsworth, CA) chromatography.
For yeast in vitro kinase assays, purified proteins were incubated with and without Psk1
in a 30 uL reaction containing 1x kinase buffer as previously described (DeMille et al., 2014).
For in vitro kinase assays using purified USF1 and hPASK proteins, reactions were run similar to
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the yeast proteins except for the following: 1 mM ATP was used and reactions were incubated
for 30 minutes. Ipp1 (expressed from plasmid pJG1025) was purified similarly as Cbf1 and
USF1, and was used as a negative control to show specificity of hPASK with USF1.
2.3.3 Mitochondrial respiration
Yeast strains not transformed with a plasmid (wild type (JGY43), psk1psk2 (JGY1244),
psk1 (JGY1348) and psk2 (JGY1349)) were grown in YPAD overnight, diluted 1:100 in
YPAGly/EtOH and grown for 13 hours. Wild type yeast (JGY43) transformed with an empty
vector (pJG725), or CBF1-deficient yeast (JGY1227) transformed with either empty vector
(pJG725), wild type Cbf1 (pJG1125), T211A-Cbf1 (pJG1335), T212A-Cbf1 (pJG1336), or
USF1 (pJG1246) were grown in selective SD-Ura media until saturated, diluted 1:100 in
SGly/EtOH-Ura and grown an additional 24-26 hours. The OD600 was taken to ensure equal
growth among strains. In experiments requiring the CBF1-deficient yeast, yeast were freshly
streaked from the freezer 48 hours prior to use to avoid selection of suppressors which were
commonly seen. High-resolution O2 consumption was determined at 37˚C using the Oroboros
O2K Oxygraph (Innsbruck, Austria). Samples were centrifuged at 5000 x g for 5 min and
resuspended in warm mitochondrial respiration buffer 05 (MiR05; 0.5 mM EGTA, 10 mM
KH2PO4, 3 mM MgCl2-6 H2O, 60 mM K-lactobionate, 20 mM HEPES, 110 mM sucrose, 1
mg/ml fatty acid free BSA, pH 7.1). After addition of sample, the chambers were
hyperoxygenated to ~350 nmol/ml. Following this, routine respiration was determined by
measuring O2 consumption in the absence of any substrate (routine). Next, EtOH was added and
then the uncoupler carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone (FCCP; 70 µM) as a
measure of maximal electron transport system capacity (E). Finally, respiration was inhibited by
the addition of the cytochrome c oxidase inhibitor, azide (20 mM) eliciting a state of residual
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oxygen consumption (ROX), which provided a control for all values. Samples were run in
triplicate and averaged.
2.3.4 TEM imaging
Wild type (JGY43), cbf1 (JGY1227) and psk1psk2 (JGY1244) yeast were grown
overnight in YPAD then diluted into YPAraffinose and grown until OD600 ~0.5. Cell size was
measured using a Moxi Flow micro cytometer (ORFLO Technologies, Hailey, ID).
Permanganate fixation protocol described by Perkins and McCaffery (Perkins and McCaffery,
2007) was followed. Samples were sectioned at 80 nm using a RMC MTX ultramicrotome with a
diamond knife then post stained with Reynold’s Lead Citrate for 10 min. Cells were observed in
a Tecnai T-12 transmission electron microscope and images recorded digitally. Mitochondrial
quantification was determined using AxioVision Rel 4.8 Software (Zeiss) as described by Braun
et al. (Braun et al., 2006). Each strain was examined in duplicate with wild type n=74, cbf1 n=73,
psk1psk2 n=69 images total per yeast strain obtained with the following criteria: 1. the image of
the cell must be at least 3 um across to ensure the slice included a majority of the cell 2. the cell
image must bear a visible nucleus 3. the cell image must appear to have an intact cell wall and 4.
the cell image must be fairly uniform in shape to exclude cells that are budding.
2.3.5 Mitochondrial isolation
Wild type (JGY 43), cbf1 (JGY1227) and psk1psk2 (JGY1244) yeast were grown in
triplicate overnight in YPAD, diluted 1:100 into YPAGly/EtOH, and grown until OD600 ~1.02.0. Preparation of Isolated Mitochondria by Differenting Centrifugation (Diekert et al., 2001)
was followed with the exception of Lyticase (Sigma) being used in place of Zymolase.
Mitochondria were quantified using the Bradford assay. For mass spectrometry analysis, 10 uL
of sample were diluted with 6X SDS sample buffer to a final concentration of 1X, and samples
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were separated on 12% SDS-PAGE until the loading dye had migrated approximately 1 cm.
Bands were then obtained using a razor blade, and submitted to the UCSD Biomolecular and
Proteomics Mass Spectrometry Facility for in-gel digestion and mass spectrometry analysis. One
sample from JGY1227 failed to give data and was resubmitted for mass spectrometry analysis in
solution (without being run on SDS-PAGE).
2.3.6 In gel digest of MS samples
Gel slices were cut to 1 mm by 1 mm cubes and destained 3 times by first washing with
100 ul of 100 mM ammonium bicarbonate for 15 minutes, followed by addition of the same
volume of acetonitrile (ACN) for 15 minutes [25]. The supernatant was removed and samples
were dried in a speedvac. Samples were then reduced by mixing with 200 µl of 100 mM
ammonium bicarbonate-10 mM DTT and incubated at 56°C for 30 minutes. The liquid was
removed and 200 ul of 100 mM ammonium bicarbonate-55 mM iodoacetamide was added to gel
pieces and incubated at room temperature in the dark for 20 minutes. After the removal of the
supernatant and one wash with 100 mM ammonium bicarbonate for 15 minutes, the same
volume of ACN was added to dehydrate the gel pieces. The solution was then removed and
samples were dried in a speedvac. For digestion, enough solution of ice-cold trypsin (0.01 ug/ul)
in 50 mM ammonium bicarbonate was added to cover the gel pieces and set on ice for 30 min.
After complete rehydration, the excess trypsin solution was removed, replaced with fresh 50 mM
ammonium bicarbonate, and left overnight at 37°C. The peptides were extracted twice by the
addition of 50 µl of 0.2% formic acid and 5% ACN and vortex mixing at room temperature for
30 min. The supernatant was removed and saved. A total of 50 µl of 50% ACN-0.2% formic acid
was added to the sample, which was vortexed again at room temperature for 30 min. The
supernatant was removed and combined with the supernatant from the first extraction. The
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combined extractions were analyzed directly by liquid chromatography (LC) in combination with
tandem mass spectroscopy (MS/MS) using electrospray ionization.
2.3.7 Preparation of MS samples in solution
Protein samples were diluted in TNE (50 mM Tris pH 8.0, 100 mM NaCl, 1 mM EDTA)
buffer. RapiGest SF reagent (Waters Corp.) was added to the mix to a final concentration of
0.1% and samples were boiled for 5 min. TCEP (Tris (2-carboxyethyl) phosphine) was added to
1 mM (final concentration) and the samples were incubated at 37°C for 30 min. Subsequently,
the samples were carboxymethylated with 0.5 mg/ml of iodoacetamide for 30 min at 37°C
followed by neutralization with 2 mM TCEP (final concentration). Proteins samples prepared as
above were digested with trypsin (trypsin:protein ratio - 1:50) overnight at 37°C. RapiGest was
degraded and removed by treating the samples with 250 mM HCl at 37°C for 1 h followed by
centrifugation at 14000 rpm for 30 min at 4°C. The soluble fraction was then added to a new
tube and the peptides were extracted and desalted using C18 desalting columns (Thermo
Scientific, PI-87782) [25-27].
2.3.8 LC-MS/MS analysis
Trypsin-digested peptides were analyzed by ultra high pressure liquid chromatography
(UPLC) coupled with tandem mass spectroscopy (LC-MS/MS) using nano-spray ionization. The
nano-spray ionization experiments were performed using a TripleTof 5600 hybrid mass
spectrometer (ABSCIEX) interfaced with nano-scale reversed-phase UPLC (Waters corporation
nano ACQUITY ) using a 20 cm-75 micron ID glass capillary packed with 2.5-µm C18 [130]
CSHTM beads (Waters corporation). Peptides were eluted from the C18 column into the mass
spectrometer using a linear gradient (5–80%) of ACN (Acetonitrile) at a flow rate of 250 μl/min
for 1 h. The buffers used to create the ACN gradient were: Buffer A (98% H2O, 2% ACN, 0.1%
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formic acid, and 0.005% TFA) and Buffer B (100% ACN, 0.1% formic acid, and 0.005% TFA).
MS/MS data were acquired in a data-dependent manner in which the MS1 data was acquired for
250 ms at m/z of 400 to 1250 Da and the MS/MS data was acquired from m/z of 50 to 2,000 Da.
The Independent data acquisition (IDA) parameters were as follows; MS1-TOF acquisition time
of 250 milliseconds, followed by 50 MS2 events of 48 milliseconds acquisition time for each
event. The threshold to trigger MS2 event was set to 150 counts when the ion had the charge
state +2, +3 and +4. The ion exclusion time was set to 4 seconds. Finally, the collected data were
analyzed using Protein Pilot 4.5 (ABSCIEX) for peptide identifications for in gel samples, or
Protein Pilot 5.0 (ABSCIEX) for the single sample submitted in solution.
2.3.9 Mitochondrial protein western blot
Mitochondria was isolated from wild type (JGY 43), cbf1 (JGY1227) and psk1psk2
(JGY1244) yeast using the same method listed previously. Protein concentration was determined
using the Bradford protein assay. An equal amount of protein was loaded to each well of a 10%
SDS-PAGE gel, separated, then transferred onto a nitrocellulose membrane. After incubation
with 5% nonfat milk in TBST, the membrane was washed two times with TBS and probed with
the selected antibody: Atp3 (the gamma subunit of the F1 sector of the F0F1ATP synthase,
1:5000, Invitrogen), Qcr7 (Subunit 7 of ubiquinol cytochrome-c reductase, complex III, 1:5000,
a generous gift from Dr. Martin Ott, (Gruschke S., et al., 2012)), Cox13 (Subunit VIa of
cytochrome c oxidase, complex IV, 1:1000, a generous gift from Dr. Martin Ott, unpublished),
and porin (1:5000, Abcam). Membranes were washed two times with TBST and once with TBS
then incubated with a 1:1000 dilution of horseradish peroxidase-conjugated anti-mouse or antirabbit antibodies for 2 hours. Blots were rinsed and then developed using the WesternBright
ECL kit (Advansta Inc) according to the manufacturer’s protocol. Each blot was stripped by
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washing the blot in Amresco gentle-review stripping buffer for 30 minutes and probed a second
time with a different antibody following the steps listed above. We ensured data was collected
for each antibody on both a fresh blot and a stripped blot, except for Atp3 which was only done
on a fresh blot due to sensitivity to the stripping buffer. Each biological replicate (n=>4) was run
in duplicate as a technical control. Bands were quantified using the ImageJ software.
2.3.10 ß-galactosidase reporter assays
A LacZ reporter plasmid (pJG1314) was constructed by amplifying LacZ from BL21DE3
E. coli with primers JG3683 and JG3684, digesting with HindIII/BamHI and ligating into a
similarly digested pRS415 vector (pJG121). Promoter regions (LAC1 (JG3440/JG3441), LAG1
(JG3442/JG3443), ATP3 (JG3671/JG3672), COX4 (JG3675/JG3676), HAP4 (JG3669/JG3670),
NDI1 (JG3679/JG3680), and QCR6 (JG3673/JG3674)) were amplified from wild type yeast
template (JGY43) and cloned into the XhoI/HindIII sites of pJG1314. Yeast strains (wild type
(JGY43), cbf1 (JGY1227) psk1psk2 (JGY1244) and psk1psk2cbf1 (JGY1261)) were transformed
with LacZ fusion plasmids containing each promoter region (pJG1321, (pLAC1-LacZ), pJG1322
(pLAG1-LacZ), pJG1315 (pATP3-LacZ), pJG1316 (pCOX4-LacZ), pJG1317 (pHAP4-LacZ),
pJG1318 (pNDI1-LacZ), pJG1320 (pQCR6-LacZ), grown in selective SD-Leu media for 2 days,
diluted 1:50 in fresh media and grown until OD600 ~0.5-1.0. ß-galactosidase assays were
performed as previously described by Stebbins and Triezenberg (Stebbins et al, 2004). Cell
extracts were normalized by the Bradford assay to ensure equal amounts of total protein were
used. Each strain was analyzed six times and averages were determined.
2.3.11 Gel shift assays
Promoter regions for LAC1 (JG3440/JG3441), LAG1 (JG3442/JG3443), ATP3
(JG3671/JG3672), and PSK1 (JG3741/JG3652) were PCR amplified from wild type yeast
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template (JGY43). ATP3* and PSK1* promoter binding mutants were made by site-directed
mutagenesis at the Cbf1 binding site using oligos JG3799/JG3800 (ATP3*) and JG3801/JG3802
(PSK1*) and were PCR amplified. Reaction mixes (20 ul) contained the PCR amplified promoter
region, either 0 ul, 3 ng, or 6 ng of purified Cbf1 protein, and gel shift binding buffer (10 mM tris
(pH 7.4), 1 mM EDTA, 50 mM KCl). Reaction mixes were incubated at room temperature for 20
minutes and analyzed by electrophoresis using 2% agarose gels.
2.3.12 ATP assays
Wild type (JGY43), cbf1 (JGY1227) and psk1psk2 (JGY1244) yeast were grown
overnight in YPAD at 30°C, then shifted to room temperature for 24 hours (to avoid suppressor
accumulation in the cbf1 strain through prolonged growth at 30°C) before dilution 1:50 into fresh
YPAD and grown for 2 hours. Cultures were then centrifuged and resuspended in 5 mL YPAGlycerol/EtOH and grown until OD600 ~0.3-0.5, about 4 hours. ATP was then measured using
the Promega Bac-titer Glo bioluminescent assay. A standard was generated using a known
concentration of ATP provided in the kit. ATP levels were normalized to viable cell counts by
plating diluted cells on YPAD.
2.3.13 ROS assays
Flow cytometry was utilized to quantify the total intracellular reactive oxygen species
(cell-ROS) and mitochondrial total reactive oxygen species (mit-ROS) adapted from (Perez et
al., 2014). The oxidant sensitive, cell permeant fluorescent probes H2DCFDA(Invitrogen) and
dihydrohodamine 123 (DHR123, Invitrogen) were used to measure cell-ROS and mit-ROS
respectively. Strains were grown in 2% YPAD overnight and then diluted 1:50 in YPAraffinose
and grown for 4 hours. Samples were aliquoted and immediately, loaded with either H2DCFDA
or DHR123 and incubated at 30˚C for 2 hours in the dark. Cells were then diluted with PBS
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buffer and immediately quantified by flow cytometry. The fluorescence was monitored in the
emission fluorescence channel FL1. The populations of cells were gated in the forward scatter
and side scatter dot plots to eliminate dead cells and cellular debris. Flowjo analytical software
was used in order to quantify ROS levels between the strains.
2.3.14 Respiration plate assays
Wild type yeast transformed with an empty vector (pJG725) or cbf1 yeast (JGY1227)
transformed with plasmids containing wild type Cbf1 (pJG1125), the empty vector, or USF1
(pJG1246) were grown 2 days in SD-Ura liquid media. Cultures were serially diluted (1/10) in
water and spotted to both selective synthetic glycerol/EtOH, raffinose, or glucose plates (control)
and incubated for 2-3 days at 30˚C.
2.4 Results
2.4.1 Psk1 inhibits respiration through phosphorylation of Cbf1 at T211
In our recent publication, the combination of threonines 211 and 212 of Cbf1 were
important for Psk1 phosphorylation and inhibition of respiration [12]. We further investigated
each of these two sites individually (T211A and T212A) through in vitro kinase assays. Mutation
of the T211 site dramatically reduced the ability of Psk1 to phosphorylate Cbf1, suggesting that
it is the critical site for Psk1 phosphorylation (Figure 2.1A). Additionally, CBF1-deficient yeast
transformed with the T211A mutant displayed a higher respiratory rate in vivo compared to both
wild type CBF1 and the T212A phosphomutant (Figure 2.1B). Both phosphomimetic forms of
T211 (T211D and T211E) were not significantly different from the controls (data not shown),
suggesting that the phosphomimetic mutations do not mimic Psk1 phosphorylation. The
phosphomimetic form of UDP-glucose pyrophosphorylase (Ugp1), a well-characterized substrate
of yeast PAS kinase, also did not mimic phospho-Ugp1 [7].
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2.4.2 Evidence for respiratory control as a specialized function of PAS kinase 1 (Psk1)
In budding yeast there are two orthologs of PAS kinase, Psk1 and Psk2 [1], which have
high sequence similarity and are partially redundant in function [28]. Many duplicated genes
arose from a whole genome duplication event that occurred in an early ancestor of yeast [29-33].
From this, duplicated proteins either gained accessory functions allowing for their selection and
maintenance, or were selected against and lost. The conservation of both Psk1 and Psk2 suggests
differential functions for these proteins, however, both proteins phosphorylate the wellcharacterized substrate Ugp1 (Smith et al., 2017). To test whether Cbf1 is a substrate of both
Psk1 and Psk2, in vitro kinase assays were performed (Figure 2.1C). Only weak phosphorylation
of wild type Cbf1 by Psk2 was observed (lower band) suggesting that Psk1 is the major
intracellular regulator of Cbf1. Note that Psk1and Psk2 autophosphorylation was observed
(upper 32P bands) and Psk2-dependent phosphorylation of Ugp1 (its known substrate) was
observed, indicating that the Psk2 protein was active. No phosphorylation of Cbf1 was seen
previously when using the kinase dead mutant of PAS kinase as control (Demille et al., 2014).
In vitro kinase assays, however, can be artifactual due to misfolded protein, the presence
of protein contaminants, differential activities due to purification artifacts etc, making in vivo
assays for Psk2 respiratory function a necessary verification (Figure 2.1D). We recently showed
that PSK1PSK2-deficient yeast have an increased respiration rate, while CBF1-deficient yeast
display a significant decrease when compared to wild type yeast [12]. To determine whether this
respiratory control is a specialized function of Psk1, we assayed respiration rates in the
individual mutant yeast (psk1 and psk2) compared to wild type and the double mutant (psk1psk2)
(Figure 2.1D). Both psk1psk2 and psk1 yeast had significantly higher maximal respiration rates
(respiration in the presence of the uncoupler FCCP) compared to wild type. There was no
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significant difference between psk2 and wild type yeast. These in vivo results are consistent with
the apparent decrease of Psk2 protein under respiratory conditions [9] as well as the decreased in
vitro phosphorylation of Cbf1 by Psk2 (Figure 2.1C), and support Psk1 as the primary ortholog
responsible for regulating respiration in yeast.
2.4.3 PAS kinase-deficient yeast have increased mitochondrial area
The observed effects on respiration could be due to several different alterations in the cell
including changes in mitochondrial mass. To test the hypothesis that PAS kinase decreases
respiration by down-regulating mitochondrial biogenesis pathways, mitochondria were viewed
by transmission electron microscopy and both the number and total area of mitochondria were
quantified in wild type, cbf1 and psk1psk2 yeast (Figure 2.1E & 2.1F). PSK1PSK2-deficient
yeast showed a significant increase in both the number of mitochondria per cell as well as
average mitochondrial area per total cell. These PAS kinase effects are consistent with the
respiration phenotype; however, Cbf1 only trended towards a decreased number of mitochondria
per cell without reaching significance. Thus, PAS kinase appeared to affect respiration by
additional Cbf1-independent pathways in both the assays for mitochondrial area and the
respiration assays (Figure 2.1D & 2.1F, and DeMille et al., 2014).
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Figure 2.1 Psk1-dependent phosphorylation of Cbf1 at T211 controlled respiration. (A & C) In vitro kinase
assays using purified Psk1 or Psk2, and Cbf1 wild type (WT) or mutant proteins incubated with
radiolabeled-ATP. Ugp1 was a positive Psk2 control and Cbf1 purification yielded two bands visible in the
Coomassie Brilliant Blue (CB) panel. Kinase reactions were separated by SDS PAGE, stained CB and
imaged using autoradiography (32P). Black arrow in C indicates Cbf1. (B) WT or CBF1-deficient (cbf1)
yeast transformed with indicated plasmids were grown in S-glycerol/EtOH media and respiration rates
measured using an Oroboros O2K Oxygraph. Routine respiration was measured, then ethanol added,
and finally, an uncoupler (FCCP) was added to represent maximal respiration. (D) WT, psk1psk2, psk1 or
psk2 yeast were grown in YPAglycerol/EtOH and respiration measured as in B. (E) Representative
pictures from transmission electron microscopy of WT, cbf1 and PAS kinase-deficient (psk1psk2) yeast.
Each yeast strain was grown in duplicate, fixed with permanganate (Perkins and McCaffery, 2007),
stained with Reynold’s Lead Citrate, then observed in a Technai T-12 transmission electron microscope.
White arrows indicate mitochondria. Scale bars= 1uM. (F) quantification of electron micrographs was
determined using AxioVision Software (74 images were used for WT, 73 for cbf1, and 69 for psk1psk2).
Error bars represent SEM. Significant p-values of data analyzed using pair wise Student’s T-Test(*) and
one-way analysis of variance (ANOVA) with Tukey’s HSD post hoc test (**) are shown.

2.4.4 Mass spectrometry reveals a dramatically altered mitochondrial proteome in CBF1deficient yeast
The fact that there was no obvious, statistical difference between mitochondrial number
or area in the wild type and CBF1-deficient yeast suggests other mechanisms of respiratory
regulation. In order to assess the major differences in the mitochondrial proteome of CBF1deficient yeast, mitochondria were purified from wild type, CBF1-deficient, and PSK1PSK2deficient yeast in triplicate, and subjected to analysis by mass spectrometry (see supplementary
data 1 files for all total proteins retrieved). Surprisingly, although no difference in mitochondrial
area was seen on a per cell basis when assessed by electron microscopy, the total amount of
mitochondrial protein harvested per 0.5 liter yeast cultures was greatly reduced, consistent with
the previously observed growth defects on respiratory carbon sources [12]. In fact, normalizing
to total cells using a flow cytometer appeared not to control for this difference because the
CBF1-deficient yeast culture contains a large proportion of alive but very sick yeast. That is,
when CBF1-deficient and wild type yeast are grown in glycerol/ETOH for six hours, normalized
by OD600 and then plated on YPAD, at 48 hours there is huge decrease in CBF1-deficient
colonies that arise. Thus, the ‘sick’ CBF1-deficient yeast may have more fragile mitochondria.
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This led to decreased detection of mitochondrial proteins in the CBF1-deficient samples
when assessed by mass spectrometry, with the total number of proteins detected for wild type
yeast (598+/-30.6 proteins) and PSK1PSK2-deficient yeast (580 +/- 62.4 proteins) being over
seven times that from the CBF1-deficient yeast (79.7 +/- 11.5 proteins). Thus, a direct
comparison of the total proteins retrieved from the three strains is hampered by the lower yield
(the CBF1-deficient yeast lacked a majority of the mitochondrial proteins detected in the wild
type and PSK1PSK2-deficient samples). To try to compensate for this discrepancy, we matched
the number of proteins retrieved from the wild type and PSK1PSK2-deficient yeast directly to the
CBF1-deficient yeast by comparing the same number of total proteins from the wild type and
PSK1PSK2-deficient yeast (proteins were chosen starting with the highest confidence proteins
until the same number of proteins were retrieved). This approach revealed several key
differences between the strains. Although there are 51 proteins common to all three strains (42 of
which are directly involved in respiration, Table 2S.1), there are 50 additional proteins (26
directly involved in respiration) common to both the wild type and PSK1PSK2-deficient yeast
that are not found in the CBF1-deficient yeast (this analysis is provided in Table 2S.1).
Volcano plots were also used to analyze the mass spectrometry data by plotting the
ANOVA p-value and log2(ratio) of the fold difference of all proteins retrieved (Figure 2.2A).
Forty-three proteins were identified as significantly different between the samples and their
changes are presented as a heat map in Fig. 2.2B. Of these 43 proteins, five were TCA cycle
enzymes (Cit1, Idh1, Kdg1, Fum1 and Mdh1), two were ATP synthase Subunits (Atp3 and
Atp15), several are mitochondrial transporters of small molecules (such as Ald4, Mcy1, Pda1,
Lpd1), and two are involved in mitochondrial protein import (Tim44 and Ssc1). There were also
several involved in the maintenance of mitochondrial DNA and reactive oxygen species (ROS)
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production and defense. The porin (Por1) protein, often used as an indication of total
mitochondria, was also selectively reduced. In addition to these classic mitochondrial proteins,
several glycolytic enzymes as well as enzymes known to associate with the outer mitochondrial
membrane were found. A few enzymes associated with the peroxisome, cytosolic ER and
nucleus were also reported. A figure representing the location, and in some cases the function, of
each of these 43 hits is provided in Fig. 2.2C. Of the 43 proteins, 40 appeared to have increased
expression in the wild type versus CBF1-deficient yeast (they are decreased in the knockout
strain), while three appeared to have decreased expression.
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Figure 2.2 Comparison of the mitochondrial proteomes from WT, cbf1 and psk1psk2 yeast by mass
spectrometry revealed 43 proteins with significantly altered expression (A) Volcano plot identified 43
proteins whose peptides were significantly different when quantified by LC-MS/MS of purified
mitochondria extracted from three independent samples of wild type (WT), CBF1-deficient (cbf1) and PAS
kinase-deficient (psk1psk2) yeast grown in S-glycerol/EtOH media. Significance determined by ANOVA is
provided on the y-axis, while log2(ratio) is given on the x-axis of the volcano plot. (B) A heat map of the
43 proteins with the protein sequence GI number provided on the left and the S. cerevisiae common
protein name provided on the right. C) A figure representing the cellular location, and in some cases the
function, of each of these 43 significantly altered proteins. Function and cellular localization were obtained
from the Saccharyomyces Genome Database.

Combined with the electron microscopy results, these results suggest that the respiration
defect observed in CBF1-deficient yeast is in specific enzymes (such the TCA cycle and ATP
synthase subunits) rather than in an equal reduction of total mitochondrial proteins. To verify
these findings, we performed western blot analysis of several common mitochondrial proteins
and compared this to the levels of Atp3 (the gamma subunit of the F1 sector of the F0F1ATP
synthase) and the porin protein, both predicted to have decreased expression from the mass
spectrometry analysis. The western blot was normalized to total mitochondrial protein because
mass spectrometry revealed many differences in proteins commonly used for normalization
(such as porin). For each strain, the mitochondria was isolated (n>=4 independent isolations),
total protein was quantified and the same amount of total protein was analyzed in technical
duplicates to check loading. The Atp3 and porin protein levels appeared significantly reduced
while electron transport proteins ubiquinol cytochrome-c reductase (Complex III) subunit 7
(Qcr7) and cytochrome c oxidase subunit VIa (Cox13) were not significantly altered (Figure
2.3). These results are consistent with the mass spectrometry analysis and suggest altered
mitochondrial function rather than proportional reduction in mitochondrial area.
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Figure 2.3 Quantification of Atp3, Qcr7, Cox13, and porin (Por1) protein in WT, cbf1, and psk1psk2 isolated
mitochondria . Each biological replicate (n=>4) was run in duplicate to control for technical issues.
Representative western blots for each protein are shown below each graph. An equal amount of protein was
loaded per sample as determined by Bradford assay with bovine serum albumin as a protein standard. Error
bars represent SEM. Data was analyzed using the one-way analysis of variance (ANOVA) with Tukey’s HSD
post hoc test. *P<0.05
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2.4.5 Cbf1 regulates transcription of ATP3 and PSK1
Large-scale transcription factor profiling [21, 34] has suggested Cbf1 as a potential player in
respiratory control, potentially identifying the direct means by which Cbf1 controls respiration. We
chose five of the respiration-associated genes reported as Cbf1-regulated in these large-scale
transcriptome studies (ATP3, COX4, HAP4, NDI1, QCR6) and cloned their promoter regions into a
LacZ fusion plasmid to test transcriptional control in vivo. Of the five genes tested, the gene
encoding F1-ATP synthase complex (ATP3) was the only one that appeared to have increased
expression due to Cbf1 under these growth conditions (Figure 2.4A). Notably, this was also the only
protein of the five previously reported respiration genes that was also retrieved from the mass
spectrometry proteome analysis discussed above. As a control for the assays, two ceramide synthase
promoters (LAC1 and LAG1) that were previously shown through ß-galactosidase assays to be
regulated by Cbf1 were also tested (Kolaczkowski et al., 2004). The LAC1 and LAG1 behaved
similarly to what Kolaczkowski et al. have reported, giving support that the assays were working
properly. However, the lack of observing effects on the other four putative targets (COX4, HAP4,
NDI1, or QCR6) may be due to unforeseen issues with the constructs, the yeast strain used, or growth
condition differences. Taken together, these results are consistent with Cbf1 upregulating respiration
(through transcriptional regulation of genes such as ATP3) and downregulating lipid biosynthesis
(through regulation of genes such as LAC1 and LAG1).
In addition to these five genes involved in respiration, PSK1 was identified as a putative Cbf1
target from among the hundreds of putative targets identified in the large-scale transcription factor
studies (Petti et al., 2012). This suggested a feedback loop, where Psk1 phosphorylates and inhibits
Cbf1, and Cbf1 in turn upregulates Psk1. The PSK1 promoter was cloned into the LacZ fusion
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plasmid and also displayed CBF1-dependent regulation (Figure 2.4A). These results support an
important interplay between the CBF1 and PSK1 and solidifies the evolutionary link between them.
To test for direct binding of Cbf1 to the ATP3 and PSK1 promoters, gel shift assays were
performed with purified promoters (DNA) and purified Cbf1 protein. As shown in Fig. 2.4C, Cbf1
appears to bind the ATP3, PSK1, and LAC1 promoters, but not the control (LAG1, which was
previously shown to be regulated by Cbf1 in an indirect manner [22]). The predicted Cbf1 consensus
site (CACGTG) was then mutated as shown in Fig. 2.4B in order to confirm specificity of binding.
Reduced binding was observed for both the mutated ATP3 and PSK1 promoters, supporting direct
Cbf1 binding (Figure 2.4C).
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Figure 2.4 Evidence for the transcriptional regulation of ATP3, LAC1, LAG1 and PSK1 by Cbf1. (A) ßgalactosidase assays of yeast transformed with LacZ fusion plasmids (to the ATP3, LAC1, LAG1 or PSK1
promoters) grown in synthetic minimal media. LacZ activity was used as a readout of transcriptional
regulation. (B) A diagram of the Cbf1 consensus binding site found in LAC1, ATP3 and PSK1 upstream
regions. LAG1 does not harbor a Cbf1 binding site, therefore, the sequence is not shown. Mutant versions of
the Cbf1 consensus in the ATP3 and PSK1 promoters were created by site-directed mutagenesis and are
shown in red. (C) Gel shifts were carried out by PCR amplifying the promoter regions of LAC1, LAG1, ATP3
and PSK1 (top), as well as promoter regions with Cbf1 binding site alterations as controls (ATP3* and PSK1*)
(bottom), then incubated with either 0 ng, 3 ng, or 6 ng of purified Cbf1 protein followed by agarose gel
electrophoresis. Error bars represent SEM. Significant p-values for condition versus WT are shown. Data was
analyzed using one-way analysis of variance (ANOVA) and Tukey’s HSD post hoc test. Each strain was
tested six times and averaged for ß-galactosidase assays.
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2.4.6 Altered ATP and ROS generation in CBF1-deficient cells
The transcriptional regulation results, in conjunction with the mass spectrometry findings,
strongly suggest that Cbf1 upregulates ATP3 to promote respiration. Therefore, we monitored ATP
production in wild type, CBF1-deficient and PSK1PSK2-deficient yeast. Unexpectedly, the CBF1deficient yeast displayed a drastically higher ATP level per cell when compared to the wild type or
PSK1PSK2-deficient yeast when using OD600 to normalize the cell count (Figure 2.5A). This effect,
however, appeared to be due to a large proportion of dead/unhealthy cells as seen with the mass
spectrometry mitochondrial preparation above because there was no significant alteration in ATP
when we normalized to total viable cell count determined by plating (Figure 2.5B). Next we
investigated whether the altered respiratory metabolism of CBF1-deficient yeast resulted in reactive
oxygen species (ROS) generation (Figure 2.5C & D). The CBF1-deficient strain appeared to have a
lower level of ROS generation than wild type yeast, consistent with decreased respiration in these
yeast and supporting the altered mitochondrial proteome discussed above.
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Figure 2.5 Cellular reactive oxygen species appeared to decrease in CBF1-deficient yeast while ATP assays
revealed no significant change. ATP levels were measured in WT, cbf1, and psk1psk2 yeast strains grown
under respiratory conditions (Gly/EtOH) using Promega’s BactTiter-Glo Microbial Cell Viability Assay, a
bioluminescent assay used for ATP quantification of bacterial or yeast cells. Yeast strains were normalized to
either total cell count determine by OD600 (A) or by viable colonies from plating (B). Assays were run in
technical duplicate and biological triplicate and results were averaged. Flow cytometry was utilized to quantify
the (C) total intracellular reactive oxygen species (cell-ROS) and (D) mitochondrial reactive oxygen species
(mit-ROS) in WT, cbf1, and psk1psk2 yeast strains. The fluorescence was monitored in the emission
fluorescence channel FL1. Error bars represent SEM. Significant p-values for condition versus WT are shown
with asterisks. *p-value was determined using one-way analysis of variance (ANOVA) and Tukey’s HSD post
hoc test.
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2.4.7 Human USF1 protein is a conserved substrate of PAS kinase in vitro and affects respiration
in vivo
Just as Cbf1 regulates lipids in yeast through transcriptional control of LAC1 and LAG1, it’s
human homolog Upstream transcription factor 1 (USF1) is a major contributor to familial combined
hyperlipidemia (FCHL) [16-20, 35-46]. These studies have provided strong evidence for the role of
USF1 in lipid regulation, but a role in respiratory regulation has not been shown. Cbf1 and USF1
have homology in the region of the PAS kinase phosphorylation site on Cbf1, just upstream of the
conserved basic helix-loop-helix domain (Figure 2.6A). To determine if USF1 is a conserved
substrate of human PAS kinase (hPASK) in vitro kinase assays were performed (Figure 2.6B). USF1
was phosphorylated in vitro a hPASK-dependent manner. The effects of USF1 on respiration were
then assessed in yeast through both respiration chamber assays (Figure 2.6C) as well as plate assays
(Figure 2.6D). The results from both assays gave supporting evidence that USF1 can complement the
respiration phenotype of CBF1-deficiency in yeast, suggesting that Cbf1/USF1 play a conserved role
in the partitioning of glucose towards respiration and away from lipid biogenesis.

35

Figure 2.6 Evidence for the phosphorylation of human USF1 by hPASK and for a conserved role in the
regulation of respiration. (A) Clustal Omega (Goujon et al., 2010; Sievers et al., 2011) alignment of the bHLH
domain region for functional orthologs of Cbf1 obtained from the Isobase database (Liao et al., 2009; Park et
al., 2011; Singh et al., 2008): S. cerevisiae (ScCbf1), H. sapiens (HsUSF1), M. musculus (MmUSF1), and C.
elegans (CeMXL-1). (B) Kinase assays using purified hPASK and USF1 proteins were run on 12% SDS page,
stained with Coomassie Brilliant Blue (CB), then imaged using autoradiography (32P). Ipp1, retrieved from a
previous screen for PAS kinase interactors (DeMille et al., 2014), was used as a negative control. (C) For
respiration assays, overnights in selective S-glucose media were switched to selective S-galactose media and
respiration rates were measured using an Oroboros O2K Oxygraph. (D) Wild type and cbf1 yeast transformed
with an empty vector, Cbf1 or USF1 were grown in selective S-glucose media. Overnights in selective Sglucose media were serially diluted in water (1:10) then plated to selective S-glycerol/EtOH, -raffinose, or glucose plates and incubated for 2-3 days at 30°C. Significant p-values for data was analyzed using pair wise
Student’s T-Test (*) and one-way analysis of variance (ANOVA) with Tukey’s HSD post hoc test (**) are
shown.
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2.5 Discussion
As the primary source of cellular energy, the regulation of mitochondrial metabolism is key
in proper glucose allocation. As such, mitochondrial dysfunction has come to the forefront of a wide
variety of disease, including diabetes, obesity, Alzheimer’s and cancer [47-49]. Despite their clear
importance, there is still much unknown about mitochondrial regulation. This study provides novel
molecular mechanisms behind the regulation of mitochondrial metabolism by PAS kinase and its
substrate Cbf1/USF1. Our results suggest that PAS kinase and Cbf1 function at a pivotal point for
partitioning glucose to respiration or to lipid biosynthesis (Figure 2.7).

Figure 2.7 A model for function of Cbf1 and PAS kinase as a key point in the partitioning of glucose for
respiration or for lipogenesis. (A) When PAS kinase is inactive, Cbf1 upregulates pathways involved in
respiration and inhibits PAS kinase expression. (B) When PAS kinase is active, Cbf1 is phosphorylated at
T211 and upregulates pathways involved in lipogenesis.

First, PAS kinase-dependent phosphorylation of Cbf1 at the critical threonine 211 site
appears to reduce cellular respiration (Figure 2.1A-D). The mechanisms behind this respiratory
phenotype were characterized by looking at mitochondrial area and the mitochondrial proteome. No
significant decrease of mitochondrial area was observed by transmission electron microscopy of
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CBF1-deficient yeast (Figure 2.1E & F), suggesting alternative methods for regulating respiration. In
contrast, PAS kinase-deficient yeast did display an increased mitochondrial area, suggesting
additional targets that may control mitochondrial biogenesis as supported by the additional affects
observed in the respiration assays (Figure 2.1 and DeMille et al., 2014). This approximately onethird increase in area may help account for the increase in respiration, however it is difficult to know
how much the mitochondrial area can directly correlate to function since the effects on mitochondrial
proteins reported in this paper show that they may not be evenly regulated.
Although the effects of CBF1 on respiration did not appear to be on mitochondrial area, an
apparent significant effect on the mitochondrial proteome was detected by mass spectrometry, with
43 proteins that appeared significantly altered in CBF1-deficient yeast (Figure 2.2). These results
indicated altered levels of key electron transport chain proteins, including a decrease in Atp3 (F1
ATP synthase) and porin levels which were confirmed by western blot (Figure 2.3).
Due to the presence of a conserved Cbf1-binding site in the ATP3 promoter, promoter ßgalactosidase and gel shift assays were performed in parallel with genes (LAC1, LAG1) involved in
lipid biosynthesis previously shown to be CBF1-regulated [22, 50] . Atp3 appeared to have CBF1dependent increased expression and Cbf1 bound the ATP3 promoter in the in vitro gel shift assays
(Figure 2.4). Thus, Cbf1 appears to upregulate respiration through ATP3 (Figure 2.2-4), and to
downregulate lipid biogenesis through LAC1 and LAG1 (Figure 2.4).
The CBF1-dependent increase of ATP3 expression suggested that ATP levels may be lower
in CBF1-deficient yeast. However, we found that while CBF1-deficient yeast had lower ROS
generation consistent with decreased respiration, no significant difference in ATP levels were
observed when levels were normalized to cell count (Figure 2.5). These results suggest that CBF1deficient yeast may produce a majority of the ATP in alternative pathways. Since 40 of the 43 high
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confidence hits from mass spectrometry displayed decreased expression in CBF1-deficient yeast,
ATP could be produced by pathways not localized to the mitochondria (such as increased
glycolysis).
In addition to Atp3, we confirmed PAS kinase 1 (PSK1) as a direct transcriptional target of
Cbf1, solidifying the importance of their interaction (Figure 2.4). From promoter ß-galactosidase
assays, CBF1-deficiency led to an almost five-fold increase in Psk1 expression, and Psk1 in turn
inhibits Cbf1 activity through phosphorylation (DeMille et al., 2014). In addition, the activation of
PAS kinase by respiratory growth conditions, and its subsequent inhibition of respiration appears
contradictory. In each of these cases, PAS kinase and/or Cbf1 appears to be providing a feedback
mechanism for delicately controlling metabolism, partitioning glucose to competing pathways and
ensuring, for example, that some lipids are produced from glucose breakdown even during times
when respiration is favored. This interplay between the two indicates a long evolutionary history,
suggesting the pathway may be conserved in higher eukaryotes.
The human homolog of Cbf1, USF1, has been associated with lipid biogenesis and
hyperlipidemia in many studies [16-20, 35-46]. Combined with our results herein Cbf1/USF1 may
play a conserved role in partitioning glucose towards respiration at the expense of lipid metabolism.
In support of this hypothesis, USF1 appears to regulate respiration in yeast (Figure 2.6C & D). The
role of PAS kinase in inhibiting Cbf1 also appears to be conserved, in that hPASK can phosphorylate
USF1 in vitro (Figure 2.6B). The conservation of the USF1/PAS kinase pathway may aid in
explaining the most dramatic phenotypes reported for PAS kinase-deficient mice, namely an
increased O2 uptake and decreased liver triglyceride accumulation [11]. Further study of how PASK
is regulating the many activities of USF1 may provide additional insight into the role of PAS kinase
in human diseases including hyperlipidemia, obesity and diabetes.
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2.7 Supplementary materials
Table 2.S1 Mitochondrial proteins identified by mass spectrometry from mitochondrial extracts of wild type
(JGY43) and PAS kinase-deficient yeast (JGY1244), but not CBF1-deficient yeast. Proteins are divided into
functional categories and are listed by protein name, accession number, the number of times the protein was
retrieved (out of three biological replicates), the average retrieval number of the protein as well as the
standard deviation of the retrieval number for strains 43 and 1244, and the description of the protein. Retrieval
numbers are included as an indication of confidence Protein functions were based off of their gi description in
NCBI, or the description in the Saccharomyces Genome Database (Cherry et al., 2012; Engel et al., 2014).
Std.
dev.
strain
43

#
strain
1244

Accession
#

#
strain
43

Ave. #
strain
43

Idh2

gi|6324709

3

TCA/Respiration/Metabolism
20.3
3.2
3
24.7

9.0

Nde1

gi|6323794

3

56.0

31.5

3

64.0

18.4

Leu4

gi|6324225

3

26.3

7.2

3

43.3

20.6

Pda1

gi|6321026

3

38.7

4.6

3

49.0

23.4

Kgd2

gi|6320352

3

35.0

10.8

3

50.3

8.4

Cyt1
Lat1

gi|6324639
gi|6324258

3
3

71.3
61.3

27.7
28.0

3
3

320.7
80.7

214.5
20.5

Ald5
Ilv1
Alo1
Cdc19
Fat2

gi|6320917
gi|6320930
gi|6323553
gi|6319279
gi|6319699

3
3
3
3
3

55.7
56.7
67.7
118.7
170.7

3.5
8.3
19.4
115.5
195.2

3
3
3
3
3

71.3
65.7
81.0
40.0
51.7

18.6
15.5
16.8
12.0
30.2

Ilv6

gi|6319837

3

53.0

11.5

3

76.3

28.3

Sdh2

gi|6322987

3

77.7

32.9

3

219.3

176.8

Lys4
Adh1
Ccp1

gi|6320440
gi|6324486
gi|6322919

3
3
3

88.3
129.3
61.7

20.6
49.0
26.9

3
3
3

192.0
89.7
48.3

96.1
27.4
18.6

Pdc1

gi|6323073

3

132.0

101.8

3

88.3

48.2

Gpd1

gi|6320181

3

151.7

131.9

3

64.3

22.2

Pdh1

gi|6325258

3

94.7

8.1

2

203.0

0.0

Eno2
Aim45

gi|6321968
gi|6325261

2
3

201.0
99.7

120.2
35.9

3
1

72.0
69.0

32.9
0.0
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Ave. #
strain
1244

Std.
dev.
strain
1244

Gene/
protein

Description

isocitrate
dehydrogenase
Mito. external NADH
dehydro.
α-isopropylmalate
synthase
α-subunit pyruvate
dehydro.
α-ketoglutarate
dehydro. subunit
Cytochrome c1
pyruvate dehydro.
component (E2)
Aldehyde dehydro.
threonine deaminase
D-arabinono-1
Pyruvate kinase
Probable AMPbinding protein
Acetolactate
synthase reg.subunit
Succinate dehydro.
subunit
homoaconitase
Alcohol dehydro.
Cytochrome-c
peroxidase
pyruvate
decarboxylase
glycerol-3-phosphate
dehydro.
putative 2methylcitrate
dehydratase
enolase
putative mammalian
ETF-α ortholog

Cdc48
Gpm1

gi|6320077
gi|6322697

2
3

167.0
158.0

0.0
80.9

3
3

71.0
81.0

Gsy2
Cyb2

gi|6323287
gi|6323587

2
2

139.0
79.0

Mss51

gi|6323232

3

91.3

Rps3
Eft1

gi|6324151
gi|6324707

3
3

103.3
108.3

43.2
81.1

3
3

74.3
49.0

13.3
14.7

Eft2

gi|6320593

3

108.3

81.1

3

49.0

14.7

Ssb1

gi|6319972

3

90.7

21.2

3

62.3

15.5

Scp160

gi|6322381

2

408.5

122.3

2

99.0

17.0

Mrpl1

gi|6320321

1

72.0

0.0

1

394.0

0.0

Mic60

gi|6322868

3

99.7

Secretion/Export/Import
70.1
2
172.0

0.0

Kar2

gi|6322426

3

89.0

30.3

3

188.7

118.3

Tom70

gi|6324208

3

60.7

11.9

3

45.3

8.1

Tim44

gi|6322167

3

96.0

14.2

3

188.7

96.5

Mmd1

gi|6322138

3

51.7

Cdc12

gi|6321899

2

87.0

1.4

Om45

gi|6322055

3

29.0

Pex11

gi|6324425

2

67.5

Ssb2

gi|6324120

3

Stress Response/Sporulation
90.7
21.2
2
70.0

11.3

Hsp82

gi|6325016

3

207.3

224.0

3

60.0

8.9

Hsc82

gi|6323840

3

207.3

224.0

3

60.0

8.9

Ssa1

gi|6319314

3

93.7

41.8

3

30.0

21.8

Rho1

gi|6325423

2

99.5

Signal Transduction
36.1
3
85.3

51.0

Erg6

gi|6323635

3

86.3

Amino Acid Synthesis
41.6
3
52.0

GTP-binding ras-like
protein

10.1

Delta(24)-sterol Cmethyltransferase

99.0
2
57.0
8.5
2
97.0
Protein Expression
18.5
2
128.5

Yeast Growth/Division
14.4
3
78.3
3

26.5
48.9
26.9
0.0
75.6

33.4

133.3

103.9

Structural
18.0
3

64.7

20.6

7.8

150.7

95.8

3
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microsomal ATPase
Phosphoglycerate
mutase
Glycogen synthase
Cytochrome b2
involved mRNA
maturation of COX1
Ribosomal protein S3
translation elongation
factor2
translation elongation
factor 2
cytoplasmic HSP70
family member
G-protein receptor of
mating
Mito.large subunit
ribosomal protein
Component of the
MICOS complex
mammalian BiP
(GPR78) homolog
mito. specialized
import receptor
48.8 kDa mito.
import protein
Deoxyhypusine
hydroxylase
10nm filaments of
septin component
mito. outer
membrane protein
Peroxisomal
membrane protein
Heat shock protein of
HSP70 family
82 kDa heat shock
protein
constitutive heat
shock protein
Heat shock protein of
HSP70 family

Bat1

gi|6322002

3

81.0

7.8

3

135.0

73.0

branched-chain
amino acid trans.

DNA Replication/Recombination
94.0
0.0
1
189.0
0.0
HMG-1 homolog
Unknown
Aim9
gi|6320924 3
60.3
11.5
3
85.0
48.5
Yer080wp
Abbreviations include dehydrogenase (dehydro.), regulatory (reg.), mitochondrial (mito), transaminase
(trans.), methyltransferase (methyl.).
Abf2

gi|6323717

1

Table 2.S2 Mitochondrial proteins identified by mass spectrometry from mitochondrial extracts of CBF1deficient yeast but not wild type (JGY43) and PAS kinase-deficient yeast (JGY1244). Proteins are divided into
functional categories and are listed by protein name, accession number, the number of times the protein was
retrieved (out of three biological replicates), the average retrieval number of the protein as well as the
standard deviation of the retrieval number, and the description of the protein. Retrieval numbers are included
as an indication of confidence. Protein functions were based off of their gi description in NCBI, or the
description in the Saccharomyces Genome Database (Cherry et al., 2012; Engel et al., 2014).
Gene/
Protein

Accession
#

#

Ave.
Std.
Description
#
dev.
TCA/Respiration/Metabolism
63
0
Lysophospholipid acyltransferase
24
0
Succinate dehydrogenase
85
0
Glucose-6-phosphoate isomerase
95
0
Glutamate synthase
Protein Expression
40
0
protein with similarity to tRNA synthetases
89
0
Ribosomal protein S25B (S31B) (rp45) (YS23)
89
0
Ribosomal protein S25A (S31A) (rp45) (YS23
90
0
U2-snRNP associated splicing factor
Secretion/Export/Import
53
0.7
Hypothetical transmembrane protein
Structural
40
0
Mitochondrial inner membrane protein of the Tim23
complex
96
0
Subunit of the NatB N-terminal acetyltransferase
Stress Response/Sporulation

Ale1
Sdh1
Pgi1
Glt1

gi|6324749
gi|6322416
gi|6319673
gi|6320030

1
1
1
1

Aim10
Rps25b
Rps25a
Hsh155

gi|6320931
gi|6323365
gi|6321464
gi|6323944

1
1
1
1

Sna1

gi|6320482

3

Mas6

gi|6324344

1

Mdm20

gi|6324497

1

Ynl194cp

gi|6324135

2

60

Yel043wp

gi|6320792

1

98

Ypr097wp

gi|6325354

1

94

Pal1

gi|6320555

1

91

0
sporulation and plasma membrane sphingolipid content
Signal Transduction
0
Cytoskeleton protein involved in intracellular signaling
0
Contains a PX domain and binds phoshoinositides
Vesicles/Endocytosis
0
Protein of unknown function maybe involved in
endocytosis
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Table 2.S3 Mitochondrial proteins identified by mass spectrometry from mitochondrial extracts of wild type
(JGY43) yeast but not CBF1-deficient (JGY1277) or PAS kinase-deficient yeast (JGY1244). Proteins are
divided into functional categories and are listed by protein name, accession number, the number of times the
protein was retrieved (out of three biological replicates), the average retrieval number of the protein as well as
the standard deviation of the retrieval number, and the description of the protein. Retrieval numbers are
included as an indication of confidence. Protein functions were based off of their gi description in NCBI, or the
description in the Saccharomyces Genome Database (Cherry et al., 2012; Engel et al., 2014).
Gene/
Protein

Accession
#

#

Ave. #

Std.
Description
dev.
TCA/Respiration/Metabolism

Mcx1
Oac1
Afg1
Leu9
Pos5
Pex22
Wbp1
Ecm31
Oar1
Rpn7
Coa1
Gif1
Lip5
Pkp1

gi|6319704
gi|6322729
gi|6320783
gi|6324682
gi|6325068
gi|6319263
gi|6320835
gi|6319653
gi|6322795
gi|6325365
gi|6322034
gi|6322215
gi|6324770
gi|6322147

2
2
2
2
2
2
3
2
2
2
2
2
2
2

331.5
346.0
353.5
357.0
371.5
386.0
387.3
402.0
414.0
415.5
419.5
430.0
448.5
457.5

Cbp6
Mrp20
Mrpl22
Mrpl49
Mrpl31

gi|6319596
gi|6320613
gi|6324152
gi|6323472
gi|6322711

2
2
3
3
2

205.0
244.0
271.3
297.7
298.0

Pet54
Nuc1
Gas1
Mrpl36
Rml2
Cox11
Msw1
Mtf2
Ydr370c

gi|6321661
gi|6322253
gi|6323967
gi|6319598
gi|6320785
gi|6325125
gi|6320474
gi|6320160
gi|6320578

2
2
2
3
2
2
3
2
2

310.0
320.0
341.0
369.0
375.0
403.5
404.7
429.5
505.5

Mdl2
Tim21
Cpr6
Bfr1
Spc3

gi|6324985
gi|6321470
gi|6323246
gi|6324772
gi|6323095

2
2
2
2
3

309.5
348.0
362.0
421.0
433.0

Aim24
Prp12
Snl1

gi|6322540
gi|6323960
gi|6322173

2
2
2

288.0
363.0
403.5

6.4
mitochondrial ClpX
162.6
mitochondrial oxaloacetate transport protein
252.4
ATPase family gene
7.1
isopropylmalate synthase
2.1
mitochondrial NADH kinase
36.8
peroxisomal membrane protein
22.4
oligosaccharyl transferase glycoprotein complex
106.1
3-methyl-2-oxobutanoate hydroxymethyltransferase
7.1
3-oxoacyl-[acyl-carrier-protein] reductase
106.8
subunit of the regulatory particle of the proteasome
38.9
assembly of the cytochrome c oxidase complex
26.9
(putative) involved in cell cycle control; Gif1p
122.3
lipoic acid synthase
99.7
mitochondrial protein kinase
Protein expression
48.1
translational activator of COB mRNA
169.7
mitochondrial ribosomal large subunit protein
127.2
mitochondrial ribosomal large subunit protein
123.1
mitochondrial 60S ribosomal protein L4
130.1
15.5 kDa mitochondrial ribosomal protein YmL31
translational activator of cytochrome c oxidase subunit
198.0
III
168.3
mitochondrial nuclease
200.8
cell surface glycoprotein 115-120 kDa
171.5
mitochondrial ribosomal protein MRPL36 (YmL36)
120.2
mitochondrial protein of the large ribosomal subunit
105.4
required for delivery of copper to Cox1p
134.8
mitochondrial tryptophanyl-tRNA synthetase
64.3
involved in mRNA splicing
21.9
mRNA 5'-end-capping quality-control protein
Secretion/Export/Import
70.0
ATP-binding cassette (ABC) transporter family member
80.6
component of the TIM23 complex
223.4
cyclophilin related to the mammalian CyP-40
110.3
involved in secretion
46.4
signal peptidase subunit
Structural
162.6
functions in determining mitochondrial architecture
4.2
Integral membrane mitochondrial protein
82.7
18.3 kD integral membrane protein
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Srp54

gi|6325345

2

490.0

Erv25

gi|6323630

2

391.5

Ypr063c
Ydl157c
Ykl053ca
Yil077c

gi|6325320
gi|6320044

2
2

379.0
395.0

Signal transduction
9.9
Signal recognition particle subunit
Endocytosis
119.5
vesicle coat component
Unknown
43.8
ER-localized protein of unknown function
228.1
unknown function

gi|6322797
gi|6322113

2
2

399.0
425.5

4.2
53.0

dubious ORF
unknown function
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CHAPTER 3: Per-Arnt-Sim Kinase (PASK) Deficiency Increases Cellular Respiration on a Standard
Diet and Decreases Liver Triglyceride Accumulation on a Western High-Fat High-Sugar Diet

The following chapter is taken from an article published in Nutrients Journal. All content and figures
have been formatted for this dissertation but it is otherwise unchanged.

3.1 Abstract
Diabetes and the related disease metabolic syndrome are epidemic in the United States, in
part due to a shift in diet and decrease in physical exercise. PAS kinase is a sensory protein kinase
associated with many of the phenotypes of these diseases, including hepatic triglyceride
accumulation and metabolic dysregulation in male mice placed on a high-fat diet. Herein we provide
the first characterization of the effects of western diet (high-fat high-sugar, HFHS) on Per-Arnt-Sim
kinase mice (PASK−/−) and the first characterization of both male and female PASK−/− mice. Soleus
muscle from the PASK−/− male mice displayed a 2-fold higher oxidative phosphorylation capacity
than wild type (WT) on the normal chow diet. PASK−/− male mice were also resistant to hepatic
triglyceride accumulation on the HFHS diet, displaying a 2.7-fold reduction in hepatic triglycerides
compared to WT mice on the HFHS diet. These effects on male hepatic triglyceride were further
explored through mass spectrometry-based lipidomics. The absence of PAS kinase was found to
affect many of the 44 triglycerides analyzed, preventing hepatic triglyceride accumulation in
response to the HFHS diet. In contrast, the female mice showed resistance to hepatic triglyceride
accumulation on the HFHS diet regardless of genotype, suggesting the effects of PAS kinase may be
masked.
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3.2 Introduction
Diabetes and the related disease metabolic syndrome are an ever-increasing epidemic in
today’s society. In 2015, 9.4% of the United States population had diabetes and the estimate for
metabolic syndrome was much higher at 30% [1,2,3]. Characterized by having a combination of
increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal
triglyceride levels, metabolic syndrome increases one’s risk for heart disease, stroke, and diabetes
[1]. The increasing rates of these diseases are in part due to a global shift toward energy-dense, highfat, low nutrient foods, combined with a decrease in physical activity [4]. As these changes affect the
body as a whole, they also challenge the cellular processes in the body as it attempts to adapt to the
new nutrient and activity levels. Nutrient sensors play a critical role in adapting to these new levels
by constantly monitoring cellular nutrients and regulating cellular pathways to maintain homeostasis
[5,6]. When dysregulation in nutrient-sensing pathways occurs, many human diseases such as
diabetes and metabolic syndrome develop.
PAS kinase is a nutrient-sensing protein kinase that is conserved from yeast to man [7]. It has
been reported to regulate many of the phenotypes associated with metabolic syndrome and/or
diabetes. PAS kinase deficiency decreases insulin production, insulin resistance, body weight, and
hepatic triglyceride accumulation, while leading to increased glycogen storage as well as metabolic
rate (for research articles and associated recent reviews see
[8,9,10,11,12,13,14,15,16,17,18,19,20,21]). For example, PAS kinase-deficient (PASK−/−) male mice
are resistant to weight gain, hepatic triglyceride accumulation and insulin resistance when placed on
a high-fat (HF) diet [18]. Without a change in food-intake or exercise, these PASK−/− male mice also
exhibit a hypermetabolic phenotype, giving off more CO2 and taking in more O2. In addition, several
mRNA’s involved in lipid biosynthesis are downregulated in PASK−/− male mice such as stearoyl53

CoA desaturase 1 (SCD1), long-chain fatty-acid elongase, fatty-acid transporter (CD36) and the
lipid-responsive nuclear hormone receptor peroxisome proliferator-activated receptor γ. This PAS
kinase-dependent decrease in hepatic triglycerides on a HF diet has been confirmed in SpragueDawley rats treated with pharmacological inhibitors [13]. Furthermore, the genetic and
pharmacological inhibition of PAS kinase in cultured cells suggests that these effects are in part due
to the inhibition of SREBP-1c proteolytic maturation [13]. PAS kinase itself is also regulated by
cellular nutrient status. PAS kinase activity and/or mRNA expression increases under conditions of
increasing nutrients, specifically upon feeding in mice [13] or at high glucose concentrations in
mammalian cells [14].
Herein we characterize the molecular effects of PAS kinase on respiration and triglyceride
metabolism, as well as how PAS kinase alters these pathways in response to diet and sex. This study
utilized cellular respiration assays, western blots for electron transport chain protein abundance, and
triglyceride metabolomics approaches. To determine the effect of diet in PASK−/− mice, we
investigated the addition of sugar to the previously reported HF diet (a high-fat high-sugar diet,
HFHS diet). This diet provides conditions where PAS kinase may be more active (high-sugar) while
also more accurately reflecting the Western Diet of today’s society (high-sugar and high-fat [22]). In
addition, we consider sex (female versus male mice) when characterizing the molecular effects of
PAS kinase, which has been not been previously reported. These findings will aid in understanding
the effects of PAS kinase as well as a HFHS diet on metabolism, shedding light on the pathways that
contribute to diseases such as metabolic syndrome and diabetes.
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3.3 Materials and methods
3.3.1 Animals
C57BL/6 (Charles River Laboratories Wilmington, MA, USA) PASK−/− mice were
generously donated by Jared Rutter (University of Utah) and were described previously [18]. Wild
type C57BL/6 were obtained from Charles River Laboratories Wilmington, MA. Age-matched male
and female wild type and PASK−/− mice, generated by breeding PASK+/− mice, were placed on a
HFHS diet (D12266Bi Condensed Milk Diet from Research Diets—16.8% kcal protein, 31.8% kcal
fat, 51.4% kcal carbs—primarily sucrose, lactic casein and corn starch) or normal chow (NC) diet
(Teklad Rodent Diet 8604 from Envigo—32% protein, 14% fat, 54% carbs—primarily dehulled
soybean meal) at 12 weeks old and maintained on the diet for a total of 25 weeks. Mice were cohoused at no more than 5 mice/cage according to sex, genotype and assigned diet in a conventional
animal house. Food and water were freely available, and mice were on a 12-h light/dark cycle. All
procedures were approved by the Brigham Young University Institutional Animal Care and Use
Committee (protocol numbers 13-1003 submitted by L.C.B.).
3.3.2 Study design
The design was based on the characterization of PASK−/− male mice on the HF diet wherein
mice were placed on the HF diet at 12 weeks, and 12–24 mice of each group were used to obtain
statistical significance of several phenotypes including body weight [18]. The study herein contains 8
experimental groups including male and female WT NC diet, WT HFHS diet, PASK+/− NC diet,
PASK+/− HFHS diet that were kept on the HFHS diet for 25 weeks prior to tissue harvest. More male
then female mice were required due to limited tissues (such as liver tissue for triglyceride assay
versus oxygen consumption assay). An account of all animals used in this study is provided in Figure
S1.
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3.3.3 Respiration assays
Liver tissue and soleus muscle was harvested and immediately used for respiration assays.
O2 consumption was determined using an O2K oxygraph (Oroboros Instruments Corp, Innsbruck,
Austria) as previously described [23]. Tissues were minced with a scalpel and permeabilized with
saponin (50 ug/ml). A baseline respiration rate was determined in each respiration chamber and then
the samples were added. Respiration was measured by following the substrate-uncoupler-inhibitortitration (SUIT) protocol: glutamate, malate, and succinate (GMS) were added to assess complex I
and II electron flow. ADP (2.5 mM) was then added to determine oxidative phosphorylation capacity
(GMSD). Following data collection, three-factor Analysis of Variance (ANOVA) was performed
using JMP Pro14 software with Tukey post-hoc test for three-factor and two-factor comparisons and
students t-test for one-factor comparisons.
3.3.4 Western blot analysis
Muscle tissue was homogenized using the Bullet Blender Storm 24 (Next Advance) in RIPA
Lysis and Extraction buffer (ThermoFisher Scientific, Waltham, MA, USA catalog number 89900)
with Halt Protease Inhibitor Cocktail (ThermoFisher Scientific, Waltham, MA, USA, catalog number
78438) using 2 mm Zirconium oxide beads. Protein concentration was determined using the Pierce
Coomassie Plus (Bradford) Assay Reagent (ThermoFisher Scientific, Waltham, MA, USA). An
equal amount of protein (2 ug) was loaded on a 12% SDS-PAGE gel, separated, then transferred onto
a nitrocellulose membrane. After incubation with 5% nonfat milk in tris-buffered saline with Tween
20 (TBST), the membrane was rinsed 2 times with tris-buffered saline (TBS) and then probed with
the OxPhosBlue Native WB Antibody Cocktail (ThermoFisher Scientific, Waltham, MA, USA)
containing mouse monoclonal NDUFA9, SDHA, UQCRC2, COX IV, and ATP5A antibodies for 2
days (these correspond to subunits of complex I, II, III, IV and V). Membranes were rinsed twice
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with TBST, once with TBS then incubated with a 1:1000 dilution of horseradish peroxidaseconjugated anti-mouse antibodies for 2 h. Blots were rinsed and then developed using the
WesternBright ECL HRP substrate (Advansta Inc., San Jose, CA, USA, catalog number K-12045D50) according to the manufacturer’s protocol. Bands were quantified using the ImageJ software
version 1.50i (National Institute of Health, Bethesda, MD, USA) [24]. Two-factor ANOVA was
performed using JMP Pro14 (version 14.0) software (SAS Institute, Cary, NC, USA) with student’s
t-test for one-factor analysis.
3.3.5 Triglyceride assays
Mouse liver samples were homogenized in 110 µL of PBS-Triton. Hepatic triglyceride levels
were measured using the BioVision (Milpitas, CA, USA) Triglyceride Quantification
Colorimetric/Fluorometric Kit (K622) according to manufacturer’s protocol, and absorbance was
measured at 530–590 nm. Protein concentration was determined using the Pierce Coomassie Plus
(Bradford) Assay Reagent (ThermoFisher Scientific, Waltham, MA, USA). Three-factor ANOVA
was performed using JMP Pro14 software with Tukey post-hoc test for three-factor and two-factor
interaction analysis and students t-test for one-factor analysis.
3.3.6 Liquid chromatography-mass spectrometry (LC/MS) lipidomics
Forty-four triglycerides were analyzed by LC/MS at the University of Utah Metabolomics
Core Facility. Triglycerides were extracted from frozen tissue in 225 µL ice-cold MeOH containing
internal standards (Avanti 860902 TG (16:0/18:1/16:0-d5) 100 µg/mL, 10 µL each/sample;
cholesterol-d7, 100 µg/mL, 20 µL each/sample) 750 µL of ice-cold MTBE (methyl tert-butyl ether)
in bead mill tubes (1.4 mm ceramic, QIAGEN, Venlo, Netherlands, catalog number 13113-50). The
sample was homogenized in one 30 s cycle, rested on ice for 15 min, then 300 µL of water was
added to induce phase separation. Samples were then centrifuged at 20,000 g for 5 min at 4 °C, the
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upper phases are collected separately and evaporated to dryness under vacuum. Triglyceride samples
are reconstituted in 200 µL ACN:H2O:IPA (1:1:2) + 0.1% formic acid and transferred to an LC/MS
vial with insert for analysis. A pooled QC sample were prepared by taking 40 µL aliquots from each
sample. Concurrently a process blank sample was brought forward. Triglyceride extracts were
separated on a Waters (Milford, MA, USA) Acquity UPLC CSH C18 1.7 µm 2.1 × 100 mm column
maintained at 60 °C connected to an Agilent (Santa Clara, CA, USA) HiP 1290 Sampler, Agilent
1290 Infinity pump, equipped with an Agilent 1290 Flex Cube and Agilent 6530 Accurate Mass QTOF dual ESI mass spectrometer. For positive mode, the source gas temperature was set to 200 °C,
with a gas flow of 11 L/min and a nebulizer pressure of 50 psig. VCap voltage was set at 5000 V,
fragmentor at 100 V, skimmer at 85 V and Octopole RF peak at 750 V. For negative mode, the
source gas temperature was set to 270 °C, with a drying gas flow of 8.5 L/min and a nebulizer
pressure of 40 psig. VCap voltage is set at 3000 V, fragmentor at 247.5 V, skimmer at 57.5 V and
Octopole RF peak at 750 V. Reference masses in positive mode (m/z 121.0509 and 922.0098) were
infused with nebulizer pressure at 2 psig, and in negative mode (1033.988, 966.0007, 112.9856 and
68.9958) were infused with a nebulizer pressure at 5 psig. Samples were analyzed in a randomized
order in both positive and negative ionization mode in separate experiments acquiring with the scan
range between m/z 100 and 1700. Mobile phase A consisted of ACN:H2O (60:40 v/v) in 10 mM
ammonium formate and 0.1% formic acid, and mobile phase B consisted of IPA:ACN:H2O (90:9:1
v/v) in 10 mM ammonium formate and 0.1% formic acid. The chromatography gradient for both
positive and negative modes started at 15% mobile phase B then increased to 30% B over 2 min, it
then increased to 52% B from 2 to 2.5 min, then increased to 82% B from 2.5 to 11 min, then
increased to 95% B from 11 to 11.5 min, then increased to 99% B from 11.5 to 13.5 min. From 13.5
to 20 min it was held at 99% B, then decreased to 15% B from 20 to 20.2 min and held there from
58

20.2 to 25 min. Flow was 0.35 mL/min throughout, injection volume was 1 µL for positive mode and
5 µL for negative mode. Tandem mass spectrometry was conducted using the same LC gradient at a
collision energy of 40 V. Results from LC/MS QQQ experiments were collected using Agilent Mass
Hunter Workstation and analyzed using the software packages Mass Hunter Qual and Mass Hunter
Quant. Results from MHQuant were exported to Excel, then normalized to internal standard,
background subtracted and divided by the tissue mass.
3.3.7 Statistical analysis
Three-factor ANOVA was used throughout the study to analyze the effects of sex, genotype,
and diet, with specific differences listed for each method. Where only male mice were use, twofactor ANOVA was used to analyze the effects of genotype and diet. Factorial ANOVA was
performed using JMP Pro14 (version 14.0) software with Tukey post-hoc test used for three-factor
(sex, genotype, and diet) and two-factor (sex and genotype, sex and diet, genotype and diet) analysis
and students t-test used for one-factor (sex, genotype, or diet) analysis. Analysis of combined factors
is indicated by “*”. For example, “sex and genotype” is written is sex*genotype.
3.4 Results
3.4.1 PAS kinase-deficient mice exhibit increased respiration when on a normal chow (NC) diet
Previous studies have reported a hypermetabolic phenotype for PASK−/− mice on a HF diet,
including increased whole-animal O2 intake and CO2 output [9]. This phenotype may be due to
increased respiration in peripheral tissues. Therefore, we measured cellular oxygen consumption
rates in female and male soleus muscle, a muscle primarily composed of slow oxidative fibers, as
well as in female and male liver tissue (Figure 3.1). The soleus tissue of both female and male
PASK−/− mice displayed a trending increase in basal respiration rate on the NC diet when compared
to WT mice upon three-factor (sex, diet, genotype) analysis. Two-factor and one-factor analysis were
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used to determine if any factors were significantly contributing to this trending increase. Two-factor
analysis using combined factors such as sex and genotype (sex*genotype, sex*diet, or
genotype*diet) revealed no significant interaction of factors, but further one-factor analysis revealed
that the PASK−/− genotype was mainly responsible for significantly increasing respiration (a ~1.5fold increase), with sex or diet having no significant effect (Figure 1A,D, GMS). In addition, a
dramatic effect in oxidative phosphorylation capacity (GMSD) was observed in soleus tissue of the
male NC diet PASK−/− mice, which showed a 2-fold increase when compared to the WT in soleus
tissue (Figure 3.1A, GMSD). A three-factor ANOVA followed by two-factor analysis indicate
sex*genotype as well as genotype*diet as the main contributing factors to this increase, suggesting a
complex interaction of these factors (Figure 1C,D). Combined, the soleus muscle results are
consistent with whole-body oxygen consumption increases in PASK−/− mice reported for the wholeanimal on a HF diet [9]. In comparison, the liver oxygen consumption rates displayed small
differences when compared to the soleus. The WT mice showed decreased basal respiration in
response to the HFHS diet, with main dependence on the genotype*diet interaction in the two-factor
analysis (Figure 3.1E). In addition, there were main dependences on sex (an increase in male) and
diet (a decrease on HFHS) in the one-factor analysis for liver oxidative phosphorylation capacity
(Figure 3.1F).
Adenosine triphosphate (ATP) assays were performed to determine if the increased capacity
for oxidative phosphorylation observed in the soleus tissue of PASK−/− mice translates to increased
ATP (Figure 3S.2). Soleus tissue from male mice was used due to the increased respiration rates
observed in this tissue on the NC diet; however, no significant differences were observed. This
inability to observe a difference may in part be due to the necessity to use mice from a later cohort of
the same breeding colony (see Figure 3S.2 legend).
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Figure 3.1 PAS kinase-deficient mice (PASK−/−) exhibit increased respiration on a normal chow diet. (A–F)
Soleus muscle and liver tissue mitochondrial O2 consumption determined according to the protocol in
Materials and Methods. Results shown are a basal respiration rate (GMS) and oxidative phosphorylation
capacity (GMSD). (A,B) three-factor analysis (sex, genotype, and diet) for (A) soleus and (B) liver tissue. (C,E)
two-factor analysis (sex and genotype, sex and diet or genotype and diet) for (C) soleus and (E) liver tissue.
(D,F) one-factor analysis (sex, genotype, or diet) for (D) soleus and (F) liver tissue. NC is Normal Chow,
HFHS is High-Fat High-Sugar diet. For all figures, error bars represent standard error of the mean (SEM).
Three-factor ANOVA was performed using JMP Pro14 software. Significant differences were further analyzed
by Tukey post-hoc test for three-factor and two-factor comparisons and students t-test for one-factor
comparisons. *p < 0.05 are reported.
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3.4.2 Decreased complex I protein is observed on the HFHS diet
To investigate the molecular mechanisms behind the increased basal and oxidative
phosphorylation capacity in PASK−/− mice soleus tissue, western blot analysis was used to quantify
central electron transport chain protein subunits including NDUFA9 (complex I), SDHA (complex
II, 70), UQCRC2 (complex III, core II), COX IV (complex IV, subunit IV), and ATP5A (complex V
alpha subunit) (Figure 2). Male mice were used due to the increased magnitude of respiration effects
observed (see Figure 3.1). Quantification of these 5 electron transport chain complexes reveals one
significant difference in the HFHS PASK−/− mice compared to the NC WT for complex I (Figure
3.2A). Further one-factor ANOVA analysis revealed that this difference is due to diet and not
genotype, with the HFHS diet decreasing complex I (Figure 3.2B). Thus, the effects of PAS kinase
on basal respiration or oxidative phosphorylation capacity in the male mice may not be detectable by
our western blot assay. For example, the effects may be on other subunits of these complexes or in
other pathways, or they may be post-translational modifications as can often be expected for a
protein kinase.
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Figure 3.2 Quantification of 5 electron transport chain complexes using homogenized soleus muscle reveals
no significant differences in the PAS kinase-deficient male (PASK−/−) mice compared to the WT. (A) Soleus
tissue was homogenized and analyzed by western blot using the OxPhosBlue Native WB Antibody Cocktail
(ThermoFisher Scientific, Waltham, MA, USA) containing mouse monoclonal NDUFA9 (complex I), SDHA
(complex II), UQCRC2 (complex III, core II), COX IV (complex IV, subunit IV) and ATP5A (complex V alpha
subunit) antibodies. Protein concentration was determined before loading using the Pierce Coomassie Plus
(Bradford) Assay Reagent (ThermoFisher Scientific, Waltham, MA, USA). The same control sample (cntrl)
was loaded on each gel for normalization between gels. (B) Plots of one-factor (genotype or diet) analysis of
complex I. (C) Representative western blots for each complex are shown. Each biological replicate n > 4 was
run in duplicate. Error bars represent SEM. Two-factor (genotype and diet) ANOVA was performed using JMP
Pro14 software with students t-test performed on significant differences, * p < 0.05 is shown.
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3.4.3 Male PASK−/− mice displayed resistance to accumulation of hepatic triglyceride when
placed on a HFHS diet
Total body weight was measured over 25 weeks, with fat pads measured at week 25 (Figure
3.3A–C). Female PASK−/− mice displayed a trend for decreased starting weight (Figure 3.3A, week 1
of diet) on the standard diet. Further factorial ANOVA analysis revealed the decreased female
PASK−/− starting weight was mainly due to independent effects of sex, genotype, and diet (Figure
3.3F, Figure 3.S3A–C). Male mice weighed significantly more than the female mice after 25 weeks
on the HFHS diet. The two-factor interaction analysis suggested these effects were due to
interactions between sex*diet and genotype*diet (Figure 3.3F and Figure 3.S3A–C). No significant
difference in weight was observed at 25 weeks when comparing the WT and PASK−/−mice on the
HFHS diet. This result is contrary to the resistance to weight gain on a HF diet reported for
PASK−/− male mice [9]. These differences could be due to the HF versus HFHS diet, statistical
analysis differences, or experimental differences since these were not performed on the same cohort.
In male HFHS mice, there was a higher percentage of both retroperitoneal and gonadal fat that was
not seen in female mice (Figure 3.3B,C). The two-factor interaction analysis suggested the main
contributing factors to be a significant interaction between sex*diet for both retroperitoneal and
gonadal fat, but not sex*genotype or genotype*diet (Figure 3.3F and Figure 3.S3D–I). Thus, no
significance was seen for the PASK−/− genotype. When liver weight was measured as a percentage of
body weight, a trending decrease in weight was seen in both male and female mice on a HFHS diet
regardless of genotype (Figure 3.3D). The two-factor interaction revealed no major contributions
from interaction, while the one-factor interaction analysis revealed diet as the only main contributing
factor (Figure 3.3F and Figure 3.S3J–L). In summary, the most significant effects on weight due to
PAS kinase deficiency appear to be decreased starting weights of female mice. Additionally, females
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do not display the same magnitude of body weight difference on the HFHS diet compared to the NC
diet as the males do, while both male and female on the HFHS diet have decreased relative liver
weight.
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Figure 3.3 PAS kinase deficiency protects against HFHS-induced accumulation of hepatic triglycerides. (A)
Body weight of male and female mice at the start of the diet (week 1, 12-week-old mice) and the end of the
diet (week 25). (B) Retroperitoneal fat, (C) gonadal fat and (D) liver weight as a percentage of Body Weight
(BW). (E) Hepatic triglyceride quantification for female and male mice using BioVision Triglyceride
Quantification kit. (F) Factorial ANOVA analysis (sex, genotype, and diet) results for the data presented in (A–
E). NC is Normal Chow diet, HFHS is High-Fat High-Sugar diet. For all figures, error bars represent SEM.
Three-factor ANOVA was performed using JMP Pro14 software with Tukey post-hoc test for three-factor and
two-factor (sex and genotype, sex and diet, or genotype and diet) comparisons and students t-test for onefactor (sex, genotype, or diet) comparisons. * p < 0.05 are shown in (A–E) for the three-factor analysis.
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Both PASK−/− male mice [18] and rats [13] were previously shown to be resistant to hepatic
triglyceride accumulation when placed on a HF diet. The effect of PAS kinase in male mice on the
HFHS diet appeared to be similar when we assayed total hepatic triglycerides with an enzymatic kit
(Figure 3.3E). Hepatic triglycerides increased in WT male mice placed on the HFHS diet, while no
significant increase occurred in PASK−/− male mice on the same diet (there was a 2.7-fold reduction
in total triglycerides when compared to the WT mice on the HFHS diet). This trend was not reflected
in the female mice, as they appeared to be resistant to hepatic triglyceride accumulation on a HFHS
diet. Factorial ANOVA revealed that male WT HFHS mice had elevated triglycerides when
compared to all other mouse groups, and indicated this difference was due to a complex, three-factor
interaction between sex, genotype, and diet (Figure 3.3F and Figure 3.S3M–O).
3.4.4 Male PASK−/− mice resist hepatic triglyceride accumulation in a relatively non-specific
manner
To determine if the PAS kinase-associated protection from triglyceride accumulation was
specific for particular triglycerides, LC/MS lipidomic analysis was performed on 6 male mice from
each of the 4 mouse groups by the University of Utah Metabolomics Core Facility. When all 44 of
the triglycerides analyzed were totaled the mice displayed a similar pattern to the enzymatic total
triglyceride quantification performed in our laboratory (which may represent far more than 44
triglycerides). An analysis of each of the triglycerides quantified in the LC/MS lipidomic study is
presented in a heat map (Figure 3.4A). PAS kinase appears to regulate triglycerides almost
indiscriminately, with the pattern of most triglycerides mimicking that which was seen in the total
triglycerides. Twenty-five triglycerides were significantly elevated in the WT mice (p < 0.05) but not
the PASK−/− mice in response to HFHS diet, 10 others are close to significance (p < 0.1). Examples
of 2 of these 25 triglycerides are shown (Figure 3.5A). The false discovery rate (FDR) q-value was
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less than 8.22% for all these 25 indicating that ~2 (2.05) may be false positives. To achieve a
predicted rate of only one false positive, a FDR q-value of <0.06 must be chosen, leaving 18
triglycerides as significant. A few triglycerides were not elevated in WT HFHS mice, suggesting that
diet did not affect the accumulation of these triglycerides. Examples from 2 of these non-affected
triglycerides are shown (Figure 3.5B). One triglyceride to note is TG (15:0_18.2_18.2) (Figure
3.5C). This triglyceride is elevated in the WT HFHS as can be expected, but it is also significantly
elevated in the PASK−/− HFHS. When the side chains of the 44 triglycerides were analyzed and
quantified as saturated fatty acid (SFA), monounsaturated fatty acid (MUFA), and polyunsaturated
fatty acid (PUFA), PAS kinase appeared to more specifically regulate SFA (Figure 3.5D–I). The
two-factor interaction analysis indicated that the SFA significance was mainly due to an interaction
between diet and genotype. In support of this effect, the 25 PAS kinase-dependent triglycerides (qvalue < 0.0822%) represented 90% of the 44 triglycerides by abundance.
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Figure 3.4 LC/MS triglyceride analysis of WT and PASK−/− male mice on NC and HFHS reveal significant
changes in individual triglycerides. A heat map LC/MS triglyceride analysis from male WT and PASK−/− mice
placed on a NC and HFHS diet (n = 6 for each of 4 sample groups) *, #, or X, p < 0.05 when analyzed by twofactor ANOVA and Tukey post-hoc test. Two-factor (genotype and diet) and one-factor (genotype or diet)
interaction analysis is provided in a table on the right with p-values and false discovery rates (FDR) given.
Significant p-values (p < 0.05) are shown in red, with alternative FDR q-value cutoff (p < 0.0599) provided in
red for comparison.
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Figure 3.5 Saturated fatty-acid side chains are elevated in WT male mice on the HFHS diet but not
PASK−/− male mice on the HFHS diet . (A) Examples of PAS kinase-dependent protection from triglyceride
accumulation. (B) Examples of triglycerides that were not significantly affected by the HFHS diet. (C) One
triglyceride that increased in response to the HFHS diet in the PASK−/− mouse. Bars represent SEM. * p <
0.05 when analyzed by two-factor ANOVA and Tukey post-hoc test. (D–F) Data in Figure 4 was analyzed for
saturated fatty acid (SFA), monounsaturated fatty acid (MUFA), and polyunsaturated fatty acid (PUFA) side
chains within each triglyceride. Side-chain abundance was calculated using mole percent ratio (percentage of
moles of each fatty-acid side chain compared to total mole concentration). p < 0.1 when analyzed by twofactor ANOVA and Tukey post-hoc test. (G–I) One-factor (genotype or diet) analysis of (D–F). p < 0.05 when
analyzed by student’s t-test.
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3.5 Discussion
The regulation of respiratory and triglyceride metabolism lies at the center of several
prevalent diseases including heart disease, obesity, diabetes, metabolic syndrome, and cancer.
Previous studies have shown PASK−/− mice to be resistant to hepatic triglyceride accumulation and
to have a whole-body hypermetabolic phenotype when placed on a HF diet [18]. In support of these
observations, we have shown PAS kinase to play a pivotal role in regulating cellular respiration in
yeast as well [25,26]. Herein we build upon these studies by performing the first characterization of
cellular respiration, quantification and analysis of hepatic triglyceride accumulation, and body
weight changes in both male and female PASK−/− mice (previous reports were solely in male mice).
Furthermore, this is the first report of these mice on a HFHS diet, a diet that may more accurately
reflect the western diet [22]. PAS kinase has been previously shown to be activated by high glucose
in mammalian tissue [14]. Due to the presence of sugar in this HFHS diet, we expected PAS kinase
to be more active and the related phenotypes to be more pronounced.
We observed increased oxygen consumption rates in PASK−/− mice in soleus muscle tissue
that was dependent on genotype (Figure 3.1). This is consistent with the whole-body
hypermetabolism (increased O2uptake and CO2 output) in PASK−/− mice placed on a HF diet [18] as
well as the increased cellular respiration rate in PAS kinase-deficient yeast [25,26]. This increase,
however, was often seen on the NC diet and was blunted on HFHS (Figure 1). Male PASK−/− mice
also displayed significant increases in the oxidative phosphorylation capacity in soleus tissue.
ANOVA analysis revealed this difference to be mainly due to complex interactions between
sex*genotype as well as genotype*diet. Overall, the effects of PAS kinase on respiratory function
were detectable on the NC diet but not the HFHS, in contrast to the whole-body hypermetabolic
phenotype reported on the HF diet [18]. This result is opposite of what we expected due to previous
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reports of PAS kinase activation by high glucose [14]. These differences may be due to many
experimental variables including single cell respiration versus whole-animal metabolism, feed and
the metabolism of feed, age of animal, in vitro versus in vivo respiration assay conditions,
generations from F0 parent, compensation by alternate pathways, etc. However, the trend of
PASK−/− displaying increased metabolism is conserved wherever we do see a difference in
respiration.
In contrast to the respiratory function, the role of PAS kinase in regulating hepatic
triglyceride accumulation is most evident in male mice on the HFHS diet (Figure 3.3E). The WT
male mice displayed a dramatic increase in hepatic triglyceride levels when placed on the HFHS diet,
whereas the PASK−/− male mice did not show any appreciable increase. This effect was similar to
that reported for the PASK−/− mice on the HF diet [18]. The female mice, in contrast, appeared to be
more resistant to liver triglyceride accumulation in response to the HFHS diet (Figure 3.3E). Our
results are consistent with previous reports that female WT mice are more resistant to triglyceride
accumulation on the HFHS diet [27]. This suggests that sex differences may be overshadowing the
role of PAS kinase in females.
LC/MS lipidomic analysis of 44 hepatic triglycerides from male mice revealed that almost all
(40/44) were elevated in response to the HFHS diet in WT mice (p < 0.05). PASK−/− mice were
resistant to accumulation of 25 of these 40 triglycerides (p < 0.05, FDR q-value < 0.0822), with
another 10 close to significance. ANOVA analysis revealed that this resistance was mainly due to the
interaction of genotype*diet rather than sex*diet or diet*genotype. Further analysis of these 44
triglycerides revealed that PAS kinase preferentially regulates saturated fatty-acid side chains (SFA)
(Figure 3.5D–I). The 25 PAS kinase-dependent triglycerides represented 90% of the 44 triglycerides
by abundance, indicating the side-chain analysis of all 44 may reveal PAS kinase-dependent effects.
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As predicted from the triglyceride data, male mice displayed an increase in total body weight
as well as retroperitoneal and gonadal fat pad (% of body weight) on the HFHS diet, while we saw
no significant increase in female mice (Figure 3.3). However, PAS kinase deficiency did not affect
body weight or fat pad weight as it did triglyceride accumulation. When looking at the combined
data for female mice (which displayed only very small changes in total body mass, fat accumulation,
or hepatic triglyceride accumulation) it appears that the HFHS diet is having a very limited effect on
female metabolism. This study highlights how diet and genetic effects may be masked by sex
differences, making it critical to continue studies of PAS kinase in both male and female mice to
truly understand how it is functioning in both sexes.
PAS kinase has been shown to be activated by high glucose in cultured human pancreatic
islet cells [14] and to be regulated by glucose levels in yeast as well [28], stimulating our interest in
the HFHS diet which more closely approximates the western diet and tends to abundant in high
fructose corn-syrup and milk products [22]. In this study, the respiratory effects observed in
PASK−/− versus WT mice occurred on the NC diet, whereas the triglyceride effects were most
significant on the HFHS diet. In addition to the experimental variabilities discussed above, these
results may indicate differential regulation of PAS kinase functions, consistent with protein kinases
regulating tens of substrates with alternate functions. They may also reflect redundant pathways that
mask PAS kinase deficiency, or genetic adaptations that have occurred in these knockout mice
[29,30,31]. Such adaptations are less likely to be obscuring our triglyceride data because
pharmacological PAS kinase inhibition has also been shown to protect against HF diet-inducted
hepatic triglyceride accumulation in rats [13].
The molecular substrates of PAS kinase that elicit the effects on respiration and triglyceride
accumulation are just beginning to be uncovered. Wu et al. recently reported PAS kinase as essential
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for SREBP-1c maturation in cultured hepatic cells [13]. SREBP-1 is clearly an important
transcription factor that drives hepatic fatty acid and triglyceride biosynthesis (for reviews see
[32,33,34] and articles therein); however, it is not the only one. Upstream stimulation factors (USFs)
are bHLH-leucine zipper transcription factors that bind as homo- or heterodimers to promoter E
boxes with the DNA sequence CANNTG and have been associated with hyperlipidemia in many
studies [35,36,37,38,39,40,41,42,43,44,45,46,47,48]. Several studies have provided evidence for the
direct regulation of fatty-acid synthase expression by USF1 and USF2 [49,50,51]. We have recently
provided evidence that PAS kinase phosphorylates and inhibits the yeast homolog of USF1 (Cbf1),
which in turn controls both cellular respiration and lipid biosynthesis in yeast [25,26]. Its mammalian
homolog, USF1, complements the respiratory defect of CBF1-deficient yeast and is phosphorylated
by hPASK in vitro [26]. USF1 and SREBP-1 have been reported to have both synergistic, direct
binding [52,53] and independent modes of action [51,54], thus PAS kinase may control triglyceride
biosynthesis through the regulation of both proteins. Our ongoing studies are focused on the role of
PAS kinase in regulating USF1 function in mammalian cells, including both respiratory and lipid
roles.
3.6 Conclusions
Herein we investigated the effects of a HFHS diet, sex and PAS kinase-deficiency on
respiratory metabolism, body, fat and liver weight, as well as hepatic triglyceride accumulation. PAS
kinase-deficiency resulted in increased basal respiration (~1.5-fold) in soleus tissue, and for male
mice, an increased oxidative phosphorylation capacity (2-fold) when on a NC diet. For WT mice, the
HFHS diet decreased basal respiration in liver tissue. Although PAS kinase-deficiency did not appear
to protect male mice from weight gain, it did decrease hepatic triglyceride accumulation significantly
on the HFHS diet, with PASK−/− male mice having a 2.7-fold decrease when compared to the WT
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mice. Female mice appeared to be protected from both weight gain and liver triglyceride
accumulation on the HFHS diet, which may mask the effects of PAS kinase in these pathways. These
results solidify PAS kinase as a regulator of cellular respiration and hepatic triglyceride
accumulation, phenotypes associated with diabetes and metabolic syndrome.
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Figure 3.S1 An account of all mice used in this study. Includes mouse number for this study, genotype, sex,
diet, Oxygen Consumption Rates in soleus tissue (OCR soleus), Oxygen Consumption Rates in liver tissue
(OCR liver), electron chain western blot (ETC WB), week 1 and week 25 BW (Body Weight), Liver Weight,
Retroperitoneal Fat weight (RetroFat), Gonadal Fat weight, total triglycerides (Total TG), triglyceride mass
spectrometry (TG MS). Mice from supplementary Figure 2 are not included because they are not otherwise
used in the study.
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Figure 3.S2 ATP levels of soleus tissue isolated from WT and PASK-/- mice on a normal chow (NC) or high fat
high sugar (HFHS) diet suggest no significant differences. Mice were from the same breading colony but an
alternate immunology study that had the same genotypes and treatments due to technical difficulties with
variability in the flash frozen samples (samples were originally flash frozen for use in both western blot or ATP
assay). To overcome these technical variabilities, soleus muscle was harvested and stored at -80°C in ATP
Assay buffer (Sigma-Aldrich Adenosine 5’-triphosphate (ATP) Bioluminescent Assay Kit (FLAA-1KT)) prior to
the assay. Soleus muscle was homogenized using the Bullet Blender Storm 24 (Next Advance) with 2mm
Zirconium oxide beads then deproteinized using the BioVision Deproteinizing Sample Preparation Kit (K808).
Due to small amount of protein (0.01ug/ul) the PCA and neutralization buffer in the kit were diluted (1:10 and
1:20 respectively) to prevent excessive PCA or neutralization buffer being added. ATP assays were run using
the Sigma-Aldrich Adenosine 5’- triphosphate (ATP) Bioluminescent assay kit (FLAA-1KT) according to
manufacturer’s protocol. Luminescence was measured using the BioTek Synergy HT Multi-mode microplate
reader. Protein concentration was determined using the Pierce Coomassie Plus (Bradford) Assay Reagent
(ThermoFisher Scientific, catalog number 23236).
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Figure 3.S3 Figures of analysis for three-factor ANOVA of mouse body weights and triglycerides. (A) Body
weight of male and female mice at the start of the diet (week 1, 12-week-old mice) and the end of the diet
(week 25). Retroperitoneal fat (D), Gonadal fat (G) and Liver weight (J) as a percentage of body weight (BW).
(M) Hepatic triglyceride quantification for male and female mice using BioVision Triglyceride Quantification kit.
(B, E, H, K, N) two-way interaction analysis of (A, D, G, J, M) respectively. (C, F, I, L,O) one-factor analysis of
(A,D, G,J, M). NC is Normal Chow diet, HFHS is High-Fat High-Sugar diet. For all figures, error bars represent
SEM. Three-factor ANOVA was performed using JMP Pro14 software with Tukey post-hoc test for three-factor
and two-factor comparisons and students t-test for onefactor comparisons. *p < 0.05 is shown.
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CHAPTER 4: The Effect of Diet, Metabolic Health, and Sex in Amyotrophic Lateral Sclerosis

The following chapter is taken from an article submitted to Nutrients Journal. All content and figures
have been formatted for this dissertation but it is otherwise unchanged.

4.1 Abstract
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease with no
known cure. Being as 90% of ALS cases are sporadic, there are many behavioral factors
hypothesized to affect ALS onset, progression, and survival. These behavioral factors include but are
not limited to cannabis use, acupuncture, functional therapy, diet, and nutritional supplements. Many
metabolic alterations occur during ALS progression including hypermetabolism, lowered BMI, and
hyperlipidemia making diet and nutritional supplements attractive treatments. Taken together, the
implications of diet and metabolic health are important to understand in ALS as these are behavioral
factors that may be modified. Interestingly, as these factors have been studied sex-dependent
differences have also been discovered, shedding light on the importance of not only understanding
the molecular pathways altered by diet and metabolic health, but understanding how sex can
influence these pathways, particularly through endogenous and exogenous sex hormones. This will
provide more effective therapeutic targets for both males and females. This review will highlight
how diet, metabolic health, and sex affect the risk and progression of ALS.
4.2 Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease, with
approximately fifteen new cases being diagnosed every day [1]. ALS is caused by progressive
degeneration of the motor neurons in the brain and spinal cord. This degeneration eventually leads to
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an inability to perform voluntary movements and typically leads to death by respiratory paralysis
within 2 to 5 years. ALS gained attention in the early 1940’s when legendary Yankee baseball player
Lou Gehrig was diagnosed and eventually succumbed to the disease. As such, ALS is often referred
to as Lou Gehrig’s disease. Although ALS has been an important topic of scientific research for
almost a century, few advancements have been made in terms of treatment. In fact, only one drug has
been FDA approved for ALS patients (Riluzole) and it has the potential to extend life by only a few
months [2]. This speaks to the complexities of the disease as safe and effective therapies are slow in
the making.
Approximately 10% of ALS cases are familial while the remaining 90% of cases are
sporadic. This means that there is likely not a single causative genetic mutation of the disease. In
1993, a mutation in superoxide dismutase 1 (SOD1) was identified in about 20% of familial ALS
cases, allowing for the development of a model to represent the disease [3]. Since its discovery,
many other genes associated with ALS have been identified, including but not limited to TARDBP,
FUS, and ATXN2. These genes have been shown to display functional overlap with mutations in
sporadic cases of ALS, making work in disease models applicable to both sporadic and familial
forms of the disease. Disease models are a breakthrough in ALS research, allowing for the study of
many factors that contribute to ALS.
Due to the largely sporadic nature of most ALS cases, behavioral factors have been
considered in ALS risk, age of onset, progression and survival time. These factors include but are not
limited to cannabis, acupuncture, diet, and nutritional supplements [for further information regarding
behavioral factors that may affect ALS, see [4]]. Diet and nutritional supplements are particularly
interesting because many ALS patients struggle to sustain a healthy weight, leading to exacerbated
disease symptoms and shorter lifespans [5]. By implementing specific dietary programs, ALS
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patients can possibly slow disease progression and improve their quality of life. Furthermore, altered
metabolic states have been detected in ALS mouse models before physical symptoms are noticeable
[6]. This has led to many studies focused on understanding how the patient’s metabolic health before
and after disease onset affects ALS and what alterations are taking place on a molecular level.
Researches have set out to identify therapies to ameliorate these metabolic alterations and restore
healthy metabolism. These studies are not only highlighting potential therapies for ALS patients, but
also how other therapies may prove detrimental to ALS patients if they negatively alter metabolism.
As diet and metabolic health have been more extensively studied, sex-specific differences
have been noticed with certain therapies. This isn’t too surprising as men are reported to be 2-3 times
more susceptible to ALS [74-77]. However, it wasn’t until 2016 that the NIH established a
requirement for sex to be reported as an important biological variable. This has led to many prior
studies being conducted in only one gender, more often males than females, potentially
overshadowing important findings that may only be present in one gender. It is important not only to
understand why ALS presents differently between the sexes, but also how different therapies may be
working between the sexes to establish a treatment that is most beneficial for each patient. This
review is focused on highlighting how diet, metabolic health, and sex factor into the risk, onset,
progression, and survival time of ALS patients and why each of these factors should be considered
when designing and analyzing therapies for ALS.
4.3 The effect of diet in ALS (summary in Table 1)
4.3.1 High-fat diet
ALS patients often present with metabolic abnormalities that increase the energy required for
their body to function. This combined with physical changes, including the inability to swallow and
changes in appetite, can lead to malnutrition as the body attempts to maintain healthy energy
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balance. Diet is a behavioral factor that can potentially compensate for the irregular energy
homeostasis and influence how the disease progresses in the individual. Diets high in fat have been
widely studied as this type of diet typically causes weight gain in healthy individuals. To determine
the benefits of a high-fat diet, a study done with over three-hundred participants revealed that a high
intake of PUFAs decreased the risk of ALS development by 50-60% [7]. A later study with over one
million participants revealed that a diet high in PUFAs decreased the risk of ALS development by
34% and suggested that it may be protective against ALS onset [8].
Beyond decreasing the risk of ALS, it is thought that a high-fat diet is beneficial in ALS
patients because it can help negate the effects of hypermetabolism, a trait prevalent in 25-68% of
sporadic ALS cases [9]. The source of hypermetabolism is largely unknown, but results suggest an
increased resting energy expenditure in ALS patients contributes to the decline in patient health [10,
11]. In TDP-43A315T and SOD-G93A ALS mouse models it has been shown that a high-fat diet can
extend lifespan by increasing fat stores and improving motor function [12, 13]. In agreement, low-fat
diets and caloric restriction hasten clinical onset and shorten lifespan [12]. One report did find that
caloric restriction improved motor function in SOD-G93A mice [14], but it also hastened clinical
onset. The contrasting diets and the resulting lifespan show that a high-fat diet can act as an essential
element in relieving hypermetabolic stress in ALS mouse models.
It is possible that hypermetabolism presents in ALS patients before neurodegeneration. In a
SOD1G86R mouse model, it was suggested that before neurodegeneration begins skeletal muscles are
in a hypermetabolic state, and they remain in a hypermetabolic state after neurodegeneration occurs
[6]. To offset this energy imbalance, a fat-enriched high-energy diet was fed to the mice after disease
onset, effectively increasing body mass and adipose tissue and extending the mean survival time by
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20% [6]. Thus, most studies support the idea of caloric supplementation rather than restriction in
ALS patients.
However, this simple statement must be taken with caution because different fats may have
different effects in ALS patients. A study done in a SOD1G93A transgenic mouse model showed
exposure to the omega-3 polyunsaturated fatty acid eicosapentaenoic acid upon onset of disease did
not affect the progression or presentation of the disease. In fact, pre-symptomatic exposure to
eicosapentaenoic acid significantly decreased lifespan [15]. This suggests further studies are needed
to understand how different fatty acids are working in these metabolic pathways of ALS and which
ones will be most beneficial for ALS patients. It also suggests the need for careful understanding of
how different diets are affecting ALS patients before disease onset so as not to hasten symptoms.
A deeper understanding of the molecular mechanisms behind a high fat diet may provide for
effective combination with drug therapies. One study reported benefits when using a calorie energy
supplemented diet (CED, a normal chow diet supplemented with fat and cholesterol) combined with
a multifunctional monoamine oxidase (MAO). The effects were additive and positively affected
motor performance as well as mouse survival in a SOD1G93A model [16]. This study suggests that an
optimized diet may be combined with a drug therapy to significantly improve patient life.
4.3.2 Glucose, sucrose, and phenols
In addition to diets focused on fats, other energy sources have been shown to improve ALS
symptoms. One study including 24 ALS patients used both a high-fat hypercaloric diet (HF/HC) and
a high-carbohydrate hypercaloric diet (HC/HC) [22]. Their results indicated that patients on a HF/HC
diet were unable to gain weight, even when consuming 174% of their estimated energy requirements.
In addition, patients on the HF/HC diet noticed uncomfortable gastrointestinal side-effects. In
contrast, patients on a HC/HC diet gained weight. Overall, they suggested a HC/HC diet as a safe
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and beneficial diet for ALS patients over a HF/HC diet [17]. Due to the small sample size, this study
would need to be replicated to confirm their results. However, the data is promising and suggests that
a high carbohydrate diet may be even more beneficial than a high fat diet and bring with it fewer
negative side-effects.
The molecular mechanisms behind the role of carbohydrates in ALS remain largely
unstudied. C. elegans models of neurodegeneration, including mutant polyglutamine, TDP-43, FUS,
and amyloid-β toxicity have been developed to study both glucose and sucrose function. It was found
that glucose and sucrose could extend lifespan of C. elegans in a dose-dependent manner by reducing
the amount of misfolded proteins. Importantly, excessive glucose in healthy controls still exhibited
its typical negative effects on lifespan, fertility, and dauer formation, highlighting the necessity of
applying the aforementioned diets only in regards to ALS therapy [18]. Furthermore, study done in a
mutant TDP-43 C. elegans model observed the effect of maple syrup on TDP-43 proteotoxicity.
Maple syrup was chosen because it was a natural product that had a very high sugar content along
with other compounds such as antioxidants and phenols. Their study showed that maple syrup could
in fact protect against TDP-43 proteotoxicity and that two specific phenols were protective in
addition to sucrose [19]. These phenols protected against hypoxic stress was well as amyloid-B and
alpha-synuclein proteotoxicity and are found in other natural products in addition to maple syrup.
This suggests that supplementation of these phenols in the diet of those with ALS may help protect
against TDP-43 proteotoxicity and extend lifespan.
A known diet that is high in phenols is the Mediterranean diet, which has also been shown to
reduce neurodegeneration through its high olive oil content [20]. SOD1G93A mice exposed to a diet
high in extra virgin olive oil showed an extended lifespan and increased motor performance [21]. A
second supportive study showed that an extra virgin olive oil extract acted as a neuroprotective agent
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in cultures obtained from a SOD1G93A mouse model [22]. The extract reduced neurodegeneration by
downregulating the amount of nitric oxide released from activated glia stimulated by the SOD1
mutation. In addition, the TLR4 signaling pathway, a known pathogenic pathway in ALS, was
inhibited by the olive oil extract. These advances in understanding may allow for extraction of
beneficial phenols from natural products such as maple syrup and olive oil that can then be easily
added to complement ALS patient’s diets, instead of replacing their preferred dietary regiment.
4.3.3 Ketogenic diet
The ketogenic diet has been considered for ALS patients as a high-fat, low-carb diet that
works to mimic carbohydrate starvation, replacing carbohydrates with ketone bodies as the main
source of energy. Initially, the ketogenic diet was employed to help those with pharmacoresistant
epilepsy. It was later applied to neurodegenerative diseases like ALS due to common metabolic
abnormalities seen in the diseases [23]. Typically, when the SOD1 mutation is present, complex I
activity of the electron transport chain and ATP production are decreased [24]. When on a ketogenic
diet, the principle ketone body, D-β-hydroxybutyrate (DBH) can prevent rotenone mediated
inhibition of complex I in a SOD1G93A transgenic mouse model [25]. Furthermore, the diet was
shown to increase total body weight and spinal cord motor neurons. This suggests that a ketogenic
diet may be working to protect against ALS by restoring the function of complex I and promoting
ATP synthesis.
A second study performed by the same group was conducted using caprylic triglyceride, also
known as fractioned coconut oil, a substance metabolized into ketone bodies. This is an attractive
substance because it could be used as an easily distributed supplement for ALS patients. They found
that caprylic triglyceride restored healthy energy metabolism, thus improving motor function in
SOD1G93A ALS mice [26]. Combined, these studies suggest that a ketogenic diet may be beneficial to
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patients with a SOD1 mutation. However, there is little data exploring how the ketogenic diet could
affect other forms of the disease, such as patients with FUS or ATXN2 mutations.
4.3.4 The Deanna Protocol
The Deanna Protocol is a nutritional supplement reported to prevent glutamate excitotoxicity
and preserve healthy metabolic function. The supplement is essentially composed of arginine-alphaketoglutarate, gamma-aminobutyric acid, a medium chain triglyceride high in caprylic acid and
Coenzyme Q10. In a SOD1G93A mouse model, mice with Deanna Protocol supplementation exhibited
improved neurological function, improved motor performance, and extended survival time when
compared to controls [27]. This suggests that using the Deanna Protocol may extend patient lifespan
as well as improve their quality of life. However, this is the only study published on the Deanna
Protocol in an ALS model, and has yet to be replicated by another group.
4.3.5 Fruits and vegetables
Fruits and vegetables have a long history of being beneficial to health, so it comes as no
surprise that they are proving to be beneficial to ALS patients as well. In a study including over 302
ALS patients, antioxidants, carotenes, fruits, and vegetables were associated with increased ALS
function [28]. When looking at the benefits of fruits and beta-carotenes specifically, increased intake
was associated with a decreased risk of sporadic ALS in a study done with seventy-seven Koreans.
Furthermore, they identified that intake of beef, fish, and fast food were associated with an increased
risk of ALS [29]. However, this is a small study and needs further verification.
One group focused on an antiocyanin-enriched extract from strawberries, a compound known
for its antioxidant, anti-inflammatory, and anti-apoptotic properties. They found that hSODG93A
mice supplemented with the extract exhibited delayed disease onset and extended survival. Improved
motor function in these mice was seen both through increased grip strength as well as histological
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analysis, which revealed healthier neuromuscular junctions and reduced astrogliosis in the spinal
cord [30]. Overall, these limited studies suggest that fruit and vegetable intake can be beneficial for
ALS patients, with no known negative consequences. For a more in depth analysis of other various
foods that affect ALS, from french fries to green tea, see [31]. In addition, dietary fiber intake has
also been considered, with no significant association reported [32].
4.3.6 Gluten-free
A somewhat controversial diet thought to benefit some patients with ALS is a gluten-free
diet. Initial studies reported a link between celiac disease or gluten insensitivity and ALS [33, 34].
However, many other studies have shown no link between the two diseases, and thus no benefit of a
gluten-free diet [35, 36]. In addition, many neurologic manifestations that present with celiac disease
may be misdiagnosed as ALS, suggesting that the link between ALS and celiac disease may not
really exist [37]. A substantial amount of data will need to be presented for a gluten-free diet to be
considered beneficial for those with ALS, unless the patient is diagnosed with gluten sensitivity or
celiac disease in addition to ALS.
4.3.7 Vitamins
The study of how vitamins affect ALS patients is somewhat limited. Many ALS patients
present with insufficient vitamin D levels, requiring vitamin D supplementation. Vitamin D
supplementation has been associated with improved gross motor function both in human and mouse
studies [38-40]. Vitamin D deficiency has had negative effects in patients and has been shown to
significantly accelerate disease progression and shorten patient lifespan [41-44]. Thus, vitamin D
supplementation may prove beneficial for ALS patients, especially when below a healthy level.
Vitamin E supplementation has been associated with a decreased risk for ALS, but studies
have not shown it to slow disease progression or extend patient lifespan [45, 46]. As such, it has been
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recommended to those with a history of familial ALS as a preventative measure [38]. For a more in
depth review of these vitamins as well as additional vitamins and their effect on ALS development or
progression see [38].
4.3.8 L-Serine
Dietary supplementation of the amino acid L-serine may also act as a neuro-protectant. Initial
findings of Paul Cox correlated cyanobacterial toxin B-N-methylamino-L-alanine (BMAA), with the
development of ALS in Guam populations [47]. This lead to further research that implicated BMAA
in the formation of neurofibrillary tangles and beta-amyloid deposits in vivo, and suggested other at
risk populations that near cyanobacterial reservoirs. This is one of the few studies on environmental
factors, however the levels of BMAA required for these effects have remained controversial.
Through this research, the supplementation of L-serine as a cellular protectant against BMAA
poisoning has led to L-serine supplementation as a potential therapeutic treatment for ALS [48].
Phase 1 clinical trials were published in 2018 reporting a 34% reduction in progression slope [49,
50].
Table 4.1 A summary of reported dietary effects on ALS onset, progression or development
Time to Other notable
Diet
Model
Sex
Outcome Survival
onset
results
High fat (PUFA)
Humans
M/F
+
n.r.
n.r.
↓ risk (50-60%.)
High fat
Humans
M/F
+
n.r.
n.r.
↓ risk (34%.)
TDP-43A315T
Delayed AMPK
High fat
M
+
↑
n.r.
mice
activation.
↑ fat storage,
SOD1G93A
High fat
↓ AMPK activity, ↑
M
+
↑
↑
mice
motor function.
SOD1G86R
↑ body mass, ↑
High fat
M
+
↑
↑
mice
adipose tissue
TDP-43G93A
Caloric restriction
M/F
n.c.
↓
↑ motor function
mice
↓ fat storage,
SOD1G93A
Caloric restriction
↑ AMPK activity, ↓
M
↓
↓
mice
motor function.
EPA administered
G93A
Eicosapentaenoic SOD1
before disease
F
↓
↑
acid
mice
onset was
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Sour
ce
[7]
[8]
[13]
[12]
[6]
[14]
[12]
[15]

detrimental to the
animal
↑ weight gain
↓weight gain
↓ autophagy, ER
stress, and muscle
damage.
Phenols GA and CA
were responsible
↓autophagy, ER
stress and muscle
damage.

HC/HC
HF/HC

Humans
Humans

M/F
M/F

+
+/-

n.r.
n.r.

n.r.
n.r.

[17]
[17]

Glucose

C. elegans
ALS models

n/a

+

↑

n.c.

Maple syrup

C. elegans
(TDP-43)

n/a

+

↑

n.r.

Extra virgin olive
oil

SOD1G93A
mice

F

+

↑

n.c.

n.r.

+

n.r.

n.r.

Neuroprotective and
prevented nitric
oxide release.

[22]

M

+

n.r.

n.r.

↑ complex I, ↑ ATP
synthesis.

[25]

[18]
[19]
[21]

Ketogenic

HEK
cells/motone
urons/glia
cultures
from
SOD1G93A
mice
SOD1G93A
mice

Ketogenic

SOD1G93A
mice

M

+

n.c.

n.r.

[26]

SOD1G93A
mice

↑ healthy energy
metabolism and ↓
disease progression

M

+

↑

n.r.

↑ survival and motor
function

[27]

Extra virgin olive
oil extract

The Deanna
Protocol

Antioxidants,
carotenes, fruits,
Humans
M/F
+
n.r.
n.r.
↑function
[28]
vegetables
Fruits and betaHumans
M/F
+
n.r.
n.r.
↓ risk
[29]
carotene
(M) male, (F) female, (+) positive, (-) negative, (↑) increased, (↓) decreased, (n.r.) not reported, (n.c.) no
change, (HC/HC) high carbohydrate/high caloric, (HF/HC) high fat/high caloric
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4.4 Metabolic factors associated with ALS (summary in Table 2)
4.4.1 BMI
The influential role of diet in ALS has brought with it a need for understanding the
metabolic health of ALS patients with respect to their Body Mass Index (BMI). It has been
shown that an increased BMI corresponds to an increased survival time in ALS [51-55], while
a decreased BMI may increase disease severity [5]. However, how BMI acts as a protecting
factor is largely unknown. As researchers have delved into this topic, sex-dependent
differences have been revealed. A study conducted in Western Europe including over fivehundred thousand individuals showed that increased pre-diagnostic body fat reduced the risk of
ALS mortality [56]. These risk factors varied between the sexes. Underweight women were
three times more likely to die from ALS, while women with increased waist/hip ratio had a
decreased risk. Men, on the other hand, showed a significant linear relationship with increased
body mass index and decreased risk.
Furthermore, sex differences were seen when body fat distribution was studied to
determine the protecting effects of visceral and subcutaneous fat [57]. Overall fat content was
unchanged between ALS patients and controls, but the composition of the fat was different.
Both males and females with ALS showed an increase in visceral fat and a decrease in
subcutaneous fat when compared to healthy controls. However, this visceral fat did not impact
ALS clinical severity or survival. Subcutaneous fat did predict survival in males, but not
females, with an increase in fat corresponding to increased survival.
The differences seen in fat composition suggest there could be an alteration in fat
metabolism in ALS patients. One study looked at the effect of TDP-43 overexpression in mice
to determine changes in metabolism [58]. They observed that when TDP-43 is knocked out of
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mice post-natal, they exhibit decreased weight loss, fat depletion, and rapid death. When TDP43 is overexpressed, mice exhibit increased fat accumulation, adipocyte hypertrophy, and
altered responses to insulin in skeletal muscle. This suggests TDP-43 as a regulator of body
mass composition and glucose homeostasis, suggesting that mutations in TDP-43 may be a
contributing factor to the metabolic abnormalities seen in ALS [58]. Future studies could
include an investigation on fat composition in these mice compared to healthy controls as well
as how diet could affect fat composition in ALS.
4.4.2 Hyperlipidemia
It is well documented that patients with ALS present with a lowered BMI and
hypermetabolism, but they also present with hyperlipidemia. It is largely unknown what is
causing hyperlipidemia in ALS patients, but research suggests that it a positive prognostic
factor for ALS patients. A study was done in 655 humans measuring different metabolic
factors including blood concentrations of triglycerides, cholesterol, low-density lipoprotein
(LDL) and high-density lipoprotein (HDL), with hyperlipidemia being measured by the amount
of total cholesterol or LDL in the serum [59]. The results revealed that hyperlipidemia was
present in two-times as many ALS patients compared to controls, with a high LDL/HDL ratio
significantly extending patient lifespan. Moreover, elevated levels of both fasting triglycerides
and cholesterol have been shown to be positive prognostic factors in ALS. Serum triglycerides
above median levels have been shown to extend patient lifespan by 14 months [60] and
elevated cholesterol levels correlated with 3.25 times improved survival time [61].
Another study considered biological changes that accompany percutaneous endoscopic
gastrostomy (gastrostomy), a process beneficial for ALS patients who have trouble swallowing
or eating enough to meet their nutritional needs. They measured levels of total cholesterol and
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low-density lipoprotein in patients before, at the time of, and after percutaneous endoscopic
gastrostomy. Their results indicated that increased variation of total cholesterol between the
three time points were indicative of decreased survival. They suggest that a diet focused on
healthy cholesterol supplementation, especially in patients with gastrostomy, may prove
beneficial in extending patient lifespan [62].
It is possible that hyperlipidemia is the result of a compensatory mechanism used to
meet the altered energy demands in ALS. SOD1G86R mice were studied in the asymptomatic
stage (65 days of age) and glycolytic muscles were shown to preferentially utilize lipids over
glucose [63]. This may prove to be detrimental to the cell as an increase in lipid by-products
can contribute to lipotoxicity and ROS production, eventually leading to denervation and
having toxic effects on mitochondria. Interestingly, oxidative muscles such as the soleus
showed no change.
In contrast, hyperlipidemia has been reported in SOD1G93A mice in the pre-symptomatic
stage, with hyperlipidemia being significantly greater in males than in females [64]. Although
in contrast to many studies reporting hyperlipidemia, it still suggests metabolic alterations are
occurring before disease onset involving lipid metabolism. Lipid metabolism has also been
shown to be altered in the gastrointestinal tract in mSOD1 mice. Lipids were both absorbed and
triglyceride-rich lipoproteins cleared in greater frequency, resulting in decreased level of
triglyceride-rich lipoproteins after eating, also known as postprandial lipemia. When
supplemented with a high-fat diet, these alterations were ameliorated and neuroprotection
occurred [65]. A high-fat diet also protected against a decrease in postprandial cholesterolemia.
This study is in agreement with previous studies, suggesting an increased lipid intake for ALS
patients to compensate for the increased energy needs.
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Recently, a study was conducted to determine risk factors associated with ALS. LDL
cholesterol and coronary heart disease were both identified as being causally linked to ALS,
and further analysis showed that the link between ALS and coronary heart disease is due to
elevated LDL cholesterol [66]. This agrees with the hyperlipidemia typically seen in ALS
patients, but it brings into question if hyperlipidemia is a factor that is detectable before
neurodegeneration occurs, and exactly why hyperlipidemia is promoted by ALS.
4.4.3 Type 2 diabetes mellitus
The contribution of type 2 diabetes to ALS development is under debate. Many studies
have reported that type 2 diabetes protects against ALS development [67-70] and it may delay
the onset of disease symptoms [71]. Others have reported that type 2 diabetes did not affect
ALS phenotypes or prognosis [72]. These conflicting results may be because an increased BMI
is often associated with type 2 diabetes and a high BMI is the underlying protecting factor.
This had led scientists to delve deeper into specific phenotypes of the disease beyond an
elevated BMI, specifically glucose homeostasis in ALS patients.
Glucose dysregulation is a common feature seen in both type 2 diabetes and ALS. A
study done in 21 ALS patients and 21 control patients looked at the response of insulin to
glucose using oral glucose tolerance tests. Those with ALS showed elevated blood glucose
levels, impaired glucose tolerance, and elevated free-fatty acids [73]. Free-fatty acids are a
known cause of insulin resistance, suggesting that ALS could be promoting type 2 diabetes-like
phenotypes in humans. This result is contrary to mouse and human studies reported [6], but it
suggested that because the patients in this study had non-SOD1 linked sporadic ALS they may
exhibit different phenotypes than SOD1 linked ALS, highlighting a common found when
studying ALS.
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Table 4.2 A summary of reported metabolic factors associated with ALS onset, progression or
development
Metabolic Factor

Model

Sex

BMI

Humans

Male/female

BMI

Humans

Male/female

BMI

Humans

Male/female

Fat Distribution

Humans

Male/female

Fat Metabolism

TDP-43
mice

Male

Humans

Male/female

Humans

Male/female

Type 2 Diabetes
Mellitus
Type 2 Diabetes
Mellitus
Type 2 Diabetes
Mellitus

Results
↑BMI associated with ↑survival
time.
↓BMI associated with ↑disease
severity
↓ BMI females have ↑ ALS (3x)
, ↑ waist/hip ratio females have
↓ risk, ↑ BMI males correlated
to ↓ risk.
↑ subcutaneous fat ↑ survival in
males only
TDP-43 overexpression has ↑
fat accumulation, ↑ adipocyte
hypertrophy, and altered insulin
responses
Protects against ALS
development
Delays onset of ALS symptoms

Does not influence ALS
phenotype or prognosis
ALS patients had ↑ blood
glucose levels, impaired
Insulin sensitivity
Humans
Male/female
glucose tolerance, and ↑ free
fatty acids
Hyperlipidemia seen in 2x as
many ALS patients, and ↑
LDL cholesterol
Humans
Male/female
LDL/HDL ratio extends patient
lifespan.
↑ triglycerides extend patient
Fasting triglycerides Humans
Male/female
lifespan by 14 months.
↑ cholesterol correlated with
Fasting cholesterol
Humans
Male/female
3.25x improved survival
Cholesterol
↑ lifespan, particularly in
Humans
Male/female
supplementation
patients with gastrostomy
SOD1G86R
Glycolytic muscles prefer lipids
Lipid metabolism by
mice
Male
over glucose, while respiratory
glycolytic muscles
muscles show no change.
Hypolipidemia observed in the
pre-symptomatic stage,
SOD1G93A
Hypolipidemia
Male/female
mice
significantly greater in male
mice.
↑ LDL cholesterol and
associated coronary heart
LDL cholesterol
Humans
Male/female
disease correlated with ALS
development
(M) male, (F) female, (+) positive, (-) negative, (↑) increased, (↓) (decreased), (BMI)
body mass index, (LDL) low density lipoprotein, (HDL) high density lipoprotein
Humans

Male/female
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Reference(s)
[51-55]
[5]
[56]
[57]
[58]
[67-70]
[71]
[72]
[73]

[59]
[60]
[61]
[62]
[63]

[64]

[66]

4.5 The effect of sex in ALS (summary in Table 3)
4.5.1 General sex differences
When reviewing diet and metabolic disease throughout this paper, it may be noticed that
many of the in vivo experiments were performed in only one sex, usually male. In papers that
included both sexes, sex specific differences were often seen [56, 57, 64]. Many studies state that
because males are more susceptible to the disease and sometimes develop more severe disease
symptoms they are a better model to study. However, differences between the sexes suggest that
there is an underlying factor protecting females, and the application of various therapies may
differ between sexes. This highlights both a need for understanding the mechanisms behind sexdependent changes in ALS as well as the need for studies to be conducted in both sexes when
possible.
The sex dependent differences in ALS point to sex hormones as being strong contributing
factors between the sexes. Many epidemiological studies have shown that women are less
susceptible to developing ALS and exhibit less severe disease progression [74-77]. However,
these differences become less significant as patients age, with reports showing post-menopausal
women being just as likely to develop ALS as men [78]. These findings point towards sex
hormones as the strong contributing factor to sex-dependent differences. Many in vivo studies
support the role of sex hormones in ALS pathology. ALS disease development and progression
is varied amongst the sexes in many ALS mouse models [79-81]. Males typically exhibit an
earlier onset of disease and females typically live longer, despite have similar symptomatic stage
durations. In addition, it has been reported that male TDP-43 transgenic mice develop a stronger
phenotype than females [82]. Males will exhibit abrupt onset of the disease around day 14-18,
while females won’t exhibit symptoms until around day 30, with only gradual development of
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disease beginning with a small tremor. It is believed that this difference is due to an approximate
2-3 fold increase in TDP-43 accumulation in the male. These sex-dependent differences seen in
disease onset and progression strongly suggest a role of sex hormones in ALS.
Sex-dependent differences have also been seen in response to exercise. Exercise is a
somewhat controversial topic in ALS, with some reports claiming benefits to the patient, others
claiming harm, and yet others reporting no change [83]. These conflicting reports are in part due
to the short lifespan following diagnosis, making the effects of exercise difficult to measure in
humans. A few groups have overcome this issue by studying the effect of exercise in mice. In
SOD1G93A mice, high-intensity endurance training was beneficial for females only, with females
having an increased survival time [84]. Male mice exhibited a hastened decrease in motor
performance and death following clinical onset. It is unknown why the females are protected
from the deleterious effects of exercise, but it is hypothesized that estrogen could be playing a
role. It is also possible that female SOD1G93A mice live longer regardless of exercise, as has been
reported [79, 80]. A second study measuring the effects of exercise in low-copy and high-copy
human SOD1G93A mice found that exercise hastened clinical onset in males only [85]. In
agreement with the previous study, exercise extended the lifespan of high-copy hSOD1 female
mice only. They suggest that because non-exercising females had more irregular estrous cycles,
they were exposed to less estrogen, and as such estrogen was acting as a protective factor in
exercising female mice.
As mentioned previously, metabolism is altered in ALS. The effect of sex-hormones on
metabolism in ALS is supported by an article showing leptin dependent changes in SOD1 mice
[86]. Leptin is a hormone that regulates satiety and energy expenditure, changing the overall
metabolic state of the organism. SOD1 mice typically exhibit hypermetabolism, but when placed
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in a leptin-deficient background they exhibit sex-dependent improvements in energy homeostasis
and decelerated disease progression [86]. Females exhibited a significant increase in survival and
motor function and a decreased energy expenditure, while males showed similar changes but
were much less drastic. Leptin is known to be affected by various hormones, including sex
hormones, suggesting that the changes seen in this study are dependent upon the sex hormones
present in the mice [86]. Further testing on how specific hormones are affecting these changes
have not been conducted but would provide significant insight into how sex hormones are
affecting metabolism in the SOD1 mouse model of ALS.
4.5.2 Endogenous estrogen
Estrogen and progesterone are the two most abundant female sex hormones. Estrogen is
primarily an ovarian sex hormone, yet it has many functions outside of those related to
reproduction. It has been reported to play a significant role in lipid and carbohydrate metabolism,
electrolyte balance, and the central nervous system [87]. The higher prevalence of ALS in males
points towards a protective effect of female sex hormones, primarily estrogen and progesterone.
In epidemiological studies, a longer exposure to endogenous estrogen combined with a longer
reproductive time-span significantly increases survival time in post-menopausal women with
ALS [88].
Decreasing the amount of endogenous estrogen has proven to have deleterious effects on
female mice. In SOD1G93A transgenic mice, ovariectomy led to acceleration of the disease,
making disease progression and lifespan comparable to male mice [89, 90]. In addition,
ovariectomy attenuated the anti-inflammatory and anti-apoptotic actions of estrogen [91]. When
supplemented with a high dose of 17beta-estradiol (E2), a form of estrogen, ovariectomized
females exhibited extended lifespan [89, 90]. In addition, male mice treated with E2 exhibited
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significantly improved motor function in addition to inflammasome activity being ameliorated
[92]. Combined, these data strongly suggest that estrogen is having a neuroprotective effect on
disease onset and progression.
4.5.3 Endogenous progesterone
In both men and women, elevated endogenous progesterone levels show a positive
correlation with survival time and time to diagnosis [93]. Few studies have been performed
examining the effect of progesterone in an in vivo model. One study hypothesized that
progesterone may be acting to delay neurodegeneration by activating autophagy in a SOD1G93A
transgenic mouse model [94]. Although the onset of disease was not shown to be affected by
progesterone, the progression of motor dysfunction was significantly delayed. After histological
examination, it was clear that the progesterone treated group exhibited reduced spinal motor
neuron death.
The effects of progesterone are reflected in the Wobbler mouse model of ALS, where
progesterone is upregulated likely as a neuroprotective response to neurodegeneration [95].
There have been many studies conducted in Wobbler mice looking at the protective effects of
progesterone (see [95-100]). However, it is important to note that the VPS54 mutation
responsible for the Wobbler mouse has not been found in ALS patients, as such the specifics on
these studies have not been included in this review [101]. It would be very interesting to replicate
the experiments performed in the Wobbler mice in different ALS mouse models.
4.5.4 Endogenous testosterone
Testosterone is primarily a male sex hormone, but altered levels of testosterone have been
reported in females with ALS. In one study, testosterone levels were elevated in females, and as
the patient aged they remained elevated instead of declining with age as they do in healthy
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controls [102]. A second study done in 92 patients reported no change in total testosterone in
either males or females with ALS. However, they did report a significant decrease in free
testosterone in those with ALS. They suggest that this difference is a result of testosterones
inability to cross the blood brain barrier in its unbound form and that it is free testosterone
impacts ALS development [103].
Interestingly, prenatal levels of testosterone may be an influencing factor in the
development of sporadic ALS. There is some evidence suggesting that by measuring and
comparing the lengths of the index finger and the ring finger (2D:4D ratio) you can crudely
estimate the exposure of testosterone in utero for both males and female, with a reduced ratio
associating with increased testosterone. In ALS patients, the 2D:4D ratio was lower than
controls, suggesting increased prenatal testosterone levels were influencing ALS development
[104]. These studies show that testosterone levels may be associated with ALS, but further
understanding is needed to truly understand how testosterone is affecting ALS patients.
4.5.5 Exogenous sex hormones
In addition to endogenous hormones affecting ALS, exogenous hormones are also an
important factor to consider, as approximately 80% of women in the United States use hormonal
contraceptives to prevent pregnancy [105]. However, there is limited research into how
exogenous hormones affect ALS onset and progression in females. In one epidemiological study
consisting of 653 patients and 1,217 controls, exogenous estrogens and progestogens were shown
decrease the chance of developing ALS in the female population [106]. In contrast, a study of
193 postmenopausal women reported oral contraceptive use was not associated with ALS risk
[107]. It is important to note that this study did not consider the other various hormonal
contraceptives, such as intrauterine devices or vaginal rings. Although inconclusive, the results
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of these epidemiological studies have pushed for a deeper understanding of the function of
exogenous sex hormones in ALS development and progression.
Table 4.3 A summary of reported sex-related differences associated with ALS onset, progression or
development
Time
Other notable
OutSurHormone
Treatment
Sex Model
to
Source
results
come vival
Onset
Abrupt disease
General sex
Observaonset in M ↑
TDP-43
+F
[82]
M/F
n.r.
n.r.
TDP-43
hormones
tional
transgenic
-M
accumulation
HighExercise beneficial
General sex
+F
↑F
↑F
SOD1G93A
endurance
M/F
for F,
[84]
hormones
mice
-M
↓M
↓M
exercise
deleterious for M
Exercise benefit
General sex
+F
↑F
for F likely due to
[85]
Exercise
M/F hSOD1 mice
n.r.
hormones
-M
↓M
↑ estrogen
↑ survival and
motor function ↓
Leptin
+F
+F
↑F
Leptin
[86]
M/F SOD1 mice
energy, stronger
deficiency
+M
+M
↑M
phenotypes in F
Lifelong
↑ lifelong exposure
Postexposure
↑ reproductive
↑
Estrogen
F
menopausal +
[88]
and
timespan
n.c.
humans
reproductive
associated with ↓
timespan
risk
SOD1G93A
Estrogen
Ovariectomy F
↓
n.c.
↓ lifespan
[89, 90]
mice
Ovariectomy
↓ ALS motor
+ estrogen
neuron
SOD1G93A
Estrogen
F
[89, 90]
+
↑
n.c
mice
supplement
progression,
ation
↑ lifespan
↑ motor function ↓
Estrogen
neurodegeneratio
G93A
SOD1
Estrogen
supplement
M
[92]
n and ↓
+
↑
n.c
mice
ation
inflammasome
activity
↓ estrogendependent antihSOD1G93A
N/A
Ovariectomy F
[91]
↓
↑
mice
inflammation and
anti-apoptosis
Elevated
↑ hypothalamicProgesterone proM/F Humans
+
↑
↓
pituitary-adrenal
[93]
gesterone
axis activation?
Pro↓ disease
gesterone
progression ↓
SOD1G93A
Progesterone
M
[94]
+
↑
n.c.
supplemenmice
spinal motor
tation
neuron death
Obser↑ testosterone
Testosterone
M/F Humans
n.r.
n.r.
n.r.
[102]
vational
levels in F ALS
Obser↓ free testosterone
Testosterone
M/F Humans
n.r.
n.r.
n.r.
[103]
vational
in ALS
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↓ lower 2D:4D
ratio in ALS,
In utero
Obsersuggesting ↑
[104]
M/F Humans
n.r.
n.r.
testosterone
vational
exposure to
testosterone in
utero contributed
Exogenous
Exogenous
estrogens and
Obser[106]
estrogen and
progestogens
F
Humans
+
n.r.
n.r.
vational
progesterone
contributed to a ↓
risk
Exogenous
PostOral contraceptive
Oral contrasex
menopausal n.c.
n.r.
n.r.
use did not impact [107]
F
ceptive use
hormones
women
ALS risk.
(M) male, (F) female, (+) positive, (-) negative, (↑) increased, (↓) decreased, (n.r.) not reported, (n.c.) no
change, (N/A) not applicable

4.6 Concluding remark
ALS is a devastating neurodegenerative disease with few treatments and no cure.
Although the cause of ALS is largely unknown, different factors have been studied in an effort to
reduce disease risk, slow disease progression, and extend survival time (Figure 1). Three of these
factors have been discussed in this review: diet, metabolic health, and sex. Diet and metabolic
health go hand in hand. ALS patients often present with altered metabolic phenotypes, including
altered fatty acid metabolism, which may be combated with the healthy dietary interventions
discussed in this review. Furthermore, metabolic health both before and after disease onset has
been shown to affect how the disease presents in the patient, with a higher BMI being associated
with decreased risk and decreased disease progression. Consistent with this finding, diets that
increase weight or contain certain poly unsaturated fatty acids (PUFAs) have been shown to
decrease disease progression both in humans an mice. Combined, these studies review both
current holistic therapies that can be applied to benefit ALS patients as well as molecular
pathways that can be targeted for future drug development.
Sex is the third factor discussed in this review. Sex hormones play an important role in
ALS independent of diet and metabolic health, with females protected from ALS development
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and more severe disease progression. In addition, this review highlighted sex discrepancies seen
in many studies involving diet and metabolic health. Unfortunately, most studies involving diet
and metabolic health only include the male population. In cases where both sexes are included,
differences between the sexes were seen which could be obstructing clear results from studies
and contributing to contradictory reports. The impact of these findings is twofold: first, it
highlights the importance of studying potential molecular pathways for drug development in both
sexes, as they may be influenced by sex-dependent factors. It would be devastating to develop a
drug intended for both sexes only to find it behaves very differently in males and females.
Second, it suggests that the metabolic abnormalities seen in ALS may differ between sexes. This
becomes important when applying holistic therapies altering diet or metabolism in both males
and females. By considering each of these factors individually, and together, it will allow for
more effective and safe therapies for ALS patients.
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Figure 4.1 Diet, metabolic health, and sex are important contributing factors to ALS onset, progression
and/or survival time . However, it is important to understand understand that each of these factors is
linked to the other and that by altering one factor it may cause repercussions in another. This suggests
mindfulness when developing models for the study of ALS.
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CHAPTER 5: Pbp1 Regulates Mitophagy through the Novel Binding Partner Ptc6

The following chapter is taken from a study currently in progress. All content and figures have
been formatted for this dissertation.

5.1 Abstract
Mutations in ataxin-2 have recently been associated with an increased risk for
Amyotrophic Lateral Sclerosis (ALS), yet little is known about the molecular pathways behind
Ataxin-2 activity. Recently, PAS kinase was identified as a novel regulator of ataxin-2 function.
In depth studies of the yeast homolog of ataxin-2, poly(A)- binding protein binding protein 1
(Pbp1), revealed that under glucose depravation, the nutrient sensing protein kinase PAS kinase
phosphorylates and activates Pbp1. This activation inhibits TORC1 function through
sequestration to stress granules, though the mechanism behind the Pbp1 and TORC1 interaction
remains unclear. In this study, 32 novel interaction partners of Pbp1 were identified. Most the
interacting partners were involved in RNA processing, but others were involved in DNA damage
response, mitophagy, and the misfolded protein response respectively. Ptc6 was identified by
yeast two-hybrid assay as a direct binding partner of Pbp1. Colocalization revealed sequestration
of Ptc6 with Pbp1 to the stress granules under nutrient depravation. Mitophagy assays showed an
expected decrease in Ptc6-deficient yeast, while Pbp1-deficient yeast exhibited a significant
increase, suggesting Pbp1 activates Ptc6 to regulate mitophagy. In the absence of Pbp1, Ptc6 is
hyperactive and the cell has increased levels of mitophagy. Quantification of total mitochondria
revealed a significant increase in Ptc6-deficient yeast, suggesting that the decreased level of
mitophagy is causing an accumulation of mitochondria. This is supported by plate respiration
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assays that show increased colony size in Ptc6-deficient yeast. Further studies are needed to
identify the health of the mitochondria in Ptc6-deficient yeast. Overall, this study provides
further characterization of the ataxin-2/pbp1 pathways and yields valuable insight into the role of
ataxin-2 in the development of ALS.
5.2 Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease. With no
known cure and only a handful of known genetic components, treatment options for patients
typically revolve around symptomatic management, such as physical therapy, pain relievers, and
dietary supplementation [1, 2]. As such, there is a desperate need for an effective drug to be
developed that will ameliorate disease symptoms and extend patient lifespan. Recently,
intermediate-length ataxin-2 polyQ repeat expansions were identified to be significantly
associated with susceptibility of ALS in humans [3]. While little is known about ataxin-2, initial
studies have revealed that reducing ataxin-2 levels in an ALS mouse model (TDP-43 mutant
mice) increases longevity [4]. These studies suggest that higher levels or altered activity of
ataxin-2 are associated with ALS progression, while lower levels of ataxin-2 appear to be
protective. Using ataxin-2 as a therapeutic target is promising, though not without side-effects,
especially when considering complete inhibition of ataxin-2. Deletion of ataxin-2 in mice has
been shown to have adverse side-effects, including obesity, insulin resistance, and
hyperlipidemia [5, 6], suggesting that the deletion significantly impairs healthy cellular
metabolism. It is unclear what other pathways are being altered in response to ataxin-2
deficiency, making regulation of ataxin-2 (restoring healthy function) an attractive therapeutic
goal.
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A newly identified regulator of ataxin-2 is PAS kinase. PAS kinase is a nutrient sensing
protein kinase that is conserved between yeast, mice, and humans [7]. In yeast, PAS kinase has
been shown directly phosphorylate and activate ataxin-2 as well as the yeast homolog of ataxin2, Pbp1 (Choksi et al, submitted). Under cellular stress, PAS kinase phosphorylates and activates
ataxin-2/Pbp1, sequestering it to the stress granule. This function is not surprising, as ATXIN2/Pbp1 are both known to localize to stress granules. When ataxin-2/Pbp1 are phosphorylated
and activated by PAS kinase in yeast, they also can sequester other proteins to stress granules.
This model has been verified by monitoring the known interaction of Pbp1 and TORC1 (Figure
5.1). ataxin-2/Pbp1 overexpression in yeast causes caffeine sensitivity, resulting in inhibition of
cellular growth through the sequestration of TORC1 to stress granules [10]. In PAS kinasedeficient yeast, ataxin-2/Pbp1 is no longer phosphorylated and activated by PAS kinase, thus
preventing the sequestration of TORC1 to stress granules and promoting cellular growth on
caffeine (11, Choksi et al, submitted).
Despite the clear importance of ataxin-2/Pbp1, only four binding partners have been
identified (Pab1, Lsm12, Pbp4, and Dhh1, which are all thought to have roles in stress granule
formation and mRNA regulation [12]. The aim of this study was to further characterize ataxin2/Pbp1 through a Pbp1 interactome performed in yeast. Identifying additional binding partners
will shed light onto the role of ataxin-2/Pbp1 in the cell, including pathways by which it may be
affecting neurodegeneration and contributing to disease phenotypes.
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Figure 5.1 PAS kinase phosphorylates and activates Pbp1/ataxin-2, causing sequestration of
Pbp1/ataxin-2. Pbp1/ataxin-2 also influences the sequestration of other proteins to the stress granules.

5.3 Materials and methods
5.3.1 Growth assays
Lists of strains, plasmids, and primers used in this study are provided in table 1. For plasmid
construction, standard PCR-based cloning methods were used. Restriction enzymes were
purchased from New England BioLabs (Ipswich, MA).
Yeast two-hybrid bait plasmid was made by PCR amplification of Pbp1 and subsequent
cloning into the EcoRI/SalI sites of pGBD-C1 yeast two-hybrid Gal4 bait vector (pJG424) [13]
(pJG1386 [JG2916/3163]). Yeast two-hybrid libraries are described in an earlier work [14].
Yeast two-hybrid Gold cells (Clontech, Mountain View, CA) were used to transform in bait and
prey plasmids for interaction studies.
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For serial dilution growth assays, spot-dilutions were performed by growing yeast in
overnight liquid culture, serially diluted 1:10 in water and spotted on selective plates as well as
control plates. Plates were incubated at 30°C for 7–10 d until colonies were apparent.
Table 5.1 Yeast strains used in this study

Reference
or source
David
Stillman
(University
of Utah,
Salt Lake
City, UT)

Strain

Background

Genotype

Abbreviation

a/ α

JGY1

W303

ade2-1 can1-100
his3-11,15 leu2-3112
trp1-1 ura3-1

WT

a

W303

Psk1::his3 ade2-1
can1-100 his3-11,15
leu2-3112 trp1-1
ura3-1

PSK2psk1

a

Grose et al.
(2007)

W303

psk2::kan-MX4 ade21 can1-100 his311,15 leu2-3112 trp11 ura3-1

PSK1psk2

a

Grose et al.
(2007)

W303

psk1::his3 psk2::kanMX4 ade2-1 can1-100
his3-11,15 leu2-3112
trp1-1 ura3-1

psk1psk2

a

Grose et al.
(2007)

S288C

PSK2-TAPtag::kanMX
ura3-0 trp1-0 SUC2
mal mel gal2 CUP1
flo1 flo8-1

WT

α

Jared
Rutter
(University
of Utah,
Salt Lake
City, UT)

Y2H Gold

a

Clontech

Y187

α

Clontech

YPAD library

α

DeMille et
al. (2014)

JGY2

JGY3

JGY4

JGY299

Y2H Gold
(JGY1031)

Y187
(JGY1073)

JGY1074

LYS2::GAL1UASGAL1TATA-His3,
GAL2UASGal2TATA-Ade2
URA3::MEL1UASMEL1TATA, AUR1CMEL1, ura3-52 his3200 ade2-101 trp1901 leu2-3, 112
gal4del gal80del metURA3::GAL1-GAL1LacZ, MEL1, ura3-52,
his3-200, ade2-101,
trp1-901, leu2-3, 112,
gal4del, gal80del,
metpGADT7 Mate and
Plate stationary phase
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YPAD library in
JGY1073
pGADT7 Mate and
Plate mid-log YPAGal
library in JGY1073

JGY1098

JGY1122

JGY1161

BY4743

S288C

JGY1383

Pbp1::KanMx4
His3-1, leu2-0, lys20,ura3-0
psk1::hygro
psk2::NAT ura3-0
trp1-0 SUC2 mal mel
gal2 CUP1 flo1 flo8-1
pJG1386 Pbp1 in
Y2H bait
ura3-52, his3-200,
ade2-101, trp1901,leu2-3,112,
gal4del

YPAGal
library

pbp1

α

α

DeMille et
al. (2014)
Janet Shaw
(University
of Utah,
Salt Lake
City, UT)

psk1psk2

α

DeMille et
al. (2015)

PBP1-Y2H
Gold

a

This study

Jared
Rutter
(University
of Utah,
Salt Lake
City, UT)
Jared
Rutter
(University
of Utah,
Salt Lake
City, UT)
Tim
Formosa
(University
of Utah,
Salt Lake
City, UT)

BY4741

His3d1, leu2DO,
met15DO, ura3DO

WT

JGY1244

BY4741

Psk2::NAT,
psk1::hygro, his3D1,
leu2DO, met15DO,
ura3DO.

psk1psk2

JGY1598

BY4741

Ptc6::kanMX, his3D1,
leu2Do, met15DO,
ura3DO

ptc6

JGY1603

BY4741

PTC6GFP::HIS3MX6, his31, leu2-0, met15-0,
ura3-0

ptc6-GFP

O’shea
collection
(ThermoFisher)

JGY1591

BY4741

OM45-GFP::His,
leu2DO, met15DO,
ura3DO

WT

This study

JGY1593

BY4741

OM45-GFP::His,
leu2DO,
met15DO,
ura3DO

pbp1

This study

JGY43
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JGY1624

JGY1594

JGY1608

JGY1623

JGY1625

BY4741

OM45-GFP::His,
leu2DO,
met15DO,
ura3DO

ptc6

This study

BY4741

OM45-GFP::His,
psk1::hygro,
psk2::nat, leu2DO,
met15DO, ura3DO

psk1psk2

This study

BY4741

OM45-GFP::His,
psk1::hygro,
psk2::nat,
pbp1::kanMX,
leu2DO,
met15DO,
ura3DO

psk1psk2pbp1

This study

BY4741

OM45-GFP::His,
psk1::hygro,
psk2::nat,
ptc6::kanMX, leu2DO,
met15DO, ura3DO

psk1psk2ptc6

This study

BY4741

OM45-GFP::His,
atg32::kanmx,
leu2DO,
met15DO,
ura3DO

atg32

This study

Table 5.2 Plasmids used in this study
Plasmid

Gene

Description

Backbone

Yeast
origin

Selection

pJG9

PSK1

Psk1 in pRS424

pRS424

2u

Trp

pJG173

PSK2

Psk2 in pJR1765B

pJR1765B

2u

Ura

pJG174

PSK2

pJR1765B

2u

Ura

pJG421

EV

YEp-GAD

2u

Leu

pJG424

EV

YEp-GBD

2u

Trp

pJG428

Library

YEp-GAD

2u

LEU

pJG429

Library

YEp-GAD

2u

LEU

pJG598

PSK1

YEp-GBD

2u

Trp

pJG725

EV

pRS416

CEN

Ura

pJG734

PBP1

pRS416

CEN

Ura

pJG858

PSK1

pRS426

2u

Ura

Psk2 K870R kinase
dead mutant
pGAD-C1 empty
Y2H prey vector
pGBD-C1 empty
Y2H bait vector
pGAD-C2 genomic
library
pGAD-C3 genomic
library
ΔN692Psk1 in
pJG425
pADH-Myc
ADH ∆N420Pbp1Myc
pGAL1-10, Psk1HIS/HA
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Reference
or source
Jared
Rutter
Jared
Rutter
Jared
Rutter
James et
al. (1996)
James et
al. (1996)
James et
al. (1996)
James et
al. (1996)
DeMille et
al. (2014)
David
Stillman
David
Stillman
DeMille et
al. (2014)

pJG859

EV

pGAL1-10, HIS/HA

pJG925

PBP1

pJG1250

PBP1

pJG1251

PBP1

pJG1271

PSK1

pJG1331

ATXN2

pJG1359

ATXN2

pJG1360

ATXN2

pJG1361

ATXN2

pJG1386

PBP1

pJG1409

PBP1

pJG1542

PBP1

pJG1523

PBP1

pJG1544

PBP1

pJG1546

PAT1

PTA1 in Y2H bait

Leu

pJG1548

Hypothetical
gene

Hypothetical gene in
Y2H bait

Leu

pJG1549

YEN1

YEN1 in Y2H bait

Leu

pJG1560

PBP1

pJG1561

PBP1

pJG1562

PBP1

Full-length Pbp1 in
pJG859
pGAL1-10,
∆N419Pbp1-Myc
pGAL1-10, Full
length Pbp1-Myc
Psk1-D1230A kinase
dead mutant
Full length ATXN2
∆N379 ATXN2 in
pJG859
∆N554 ATXN2 in
pJG859
∆N700 ATXN2 in
pJG859
∆N419Pbp1 in
pJG424
Full length Pbp1 in
pJG725
Pbp1 with mutations:
S106A, T193A,
S436A,
S479A,T708A,T718A
made with pJG1251
Pbp1 with mutations:
S106A, T193A,
T355A, S436A,
S479A,T708A made
with pJG1251
Pbp1 with mutations:
S106A, T215A,
T355A, S436A,
S479A,T708A,T718A
made with pJG1251

Full length Pbp1 in
pJG859
Pbp1 with mutations:
S106A, T193A,
S436A,
S479A,T708A,T718A
made with pJG12560
Pbp1 with mutations:
S106A, T193A,
T355A, S436A,

DeMille et
al. (2014)
DeMille et
al. (2015)
DeMille et
al. (2015)
DeMille et
al. (2015)
DeMille et
al. (2014)
Sino
Biological
Inc.

pRS426

2u

Ura

pRS426

2u

Ura

pRS426

2u

Ura

pRS426

2u

Ura

pRS426

2u

Ura

pGEM-T

2u

Ura

pRS426

2u

Ura

This Study

pRS426

2u

Ura

This Study

pRS426

2u

Ura

This Study

pRS416

CEN

Ura

This Study

pRS416

CEN

Ura

This Study

pRS416

CEN

Ura

This Study

pRS416

CEN

Ura

This Study

pRS416

CEN

Ura

This Study
DeMille et
al. (2014)
DeMille et
al. (2014)
DeMille et
al. (2014)

pRS426

2u

Ura

This Study

pRS426

2u

Ura

This Study

pRS426

2u

Ura

This Study
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S479A,T708A made
with pJG1560
Pbp1 with mutations:
S106A, T215A,
T355A, S436A,
S479A,T708A,T718A
made with pJG1560

pJG1563

PBP1

pRS426

pJG1572

SEC61

SEC61 in Y2H bait

Leu

pJG1573

PTC6

PTC6 in Y2H bait

Leu

pJG1574

MUM2

Mum2 in Y2H bait

Leu

pJG1575

PKH1

PKH1 in Y2H bait

Leu

pJG1669

PBP1

PBP1-RFP

pJG1690

SEC63

Sec63-RFP

pRS426

2u

2u

Ura

This Study
DeMille et
al. (2014)
DeMille et
al. (2014)
DeMille et
al. (2014)
DeMille et
al. (2014)

Ura

This Study

Ura

Katrina
Cooper

Table 5.3 Primers used in this study
Primer
Sequence
JG2335
TTCGATGATGAAGATACC
JG2761
CTATTCGATGATGAAGATACCCCACC
JG2762
AGATGGTGCACGATGCACAG
JG2916
GCCTCGAGGTTTATGGCCACTGGTACTACTATTATGG
JG2917
GGCGAATTCATGAAGGGAAACTTTAGGAAAAGAG
JG2953
GAAGGAAGGAAAGCTCAATTGGGAG
JG2954
GATTGAAATACTGATTACTTAAAATTTGC
JG2993
CGCCAGGGTTTTCCCAGTC
JG3037
CAACCATAGGATGATAATGCGATTAG
JG3136
GGCGAATTCTCGTTGCCTCCAAAACCGATCAGC
JG3384
GGCGAATTCATGTCGTTGCCTCCAAAACCGATCAGC
JG3704
GGCGTCGACTTACAACTGCTGTTGGTGGTGGGC
JG3758
GGCCAATTGATGCGCTCAGCGGCCGC
JG3759
GGCCAATTGATGACCCCCAGTGGGCCAGTTCTTG
JG3760
GGCCAATTGATGTCGCCTTGCCCATCTCCTTCC
JG3761
GGCCAATTGATGCTCACAGCCAATGAGGAACTTGAG
JG3854
GGCGTCGACGCAACTGCTGTTGGTGGTGGGC

5.3.2 Yeast 2-Hybrid screening
A yeast 2-hybrid system was used to look for a protein-protein interaction. The yeast 2hybrid modifies the transcription factor for the Gal4 promoter. The transcription factor has a
DNA binding domain and an activation domain that recruits RNA polymerase. The yeast 2hybrid system cleaves the activation and binding domain and fuses them with a protein that will
either serve as the bait (bound to binding domain) or prey (bound to activation domain). When
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the two proteins interact in the cell it now allows for the Gal4 transcription factor binding
domain and activation domain to become close enough to each other to recruit RNA polymerase
to the promoter region and allow for expression of the reporter genes [15]. Pbp1 was cloned into
binding domain (pJG1386) and the library was previously cloned into activation domain [14]
(pJG428, pJG429, JGY1079 and JGY1098). Yeast containing both plasmids were selectively
grown on SD-Leu-Trp. Colonies were then streaked onto selective media SD-Leu-Trp-His-Ade,
where growth indicates a protein-protein interaction due to expression of reporter genes.
5.3.3 Yeast 2-Hybrid screening by mating
For cDNA library screens, α haploid yeast harboring a cDNA Y2H prey library
(JGY1074 and JGY1098) [14] was mated to a haploid yeast harboring ΔN419Pbp1 Bait
(JGY1383) in 2X YPAD for 24 hours at 30°C. Yeast cells where then pelleted and diluted using
10mL of SD-Leu-Trp media followed by plating 100uL on 100 SD-Leu-Trp-His-Ade plates.
5.3.4 Yeast 2-Hybrid screening by transformation
For genomic library screens, the Y2HGold (Clontech) strain bearing ΔN419Pbp1 Bait
(JGY1383) was transformed with genomic libraries (pJG428, or pJG429) obtained from David
Stillman, University of Utah [13]. Yeast cells where then pelleted and diluted using 10mL of SDLeu-Trp media followed by plating 100uL on 100 SD-Leu-Trp-His-Ade plates.
5.3.5 Colony check and dependency assay
Colonies that arose on Y2H selection plates (SD-leu-trp-his-ade) were again patched on
SD-leu-trp-his-ade plates for validation. The library plasmid inserts were then identified by
colony PCR with subsequent sequencing (Brigham Young University DNA sequencing center)
and national center for biotechnology information (NCBI) BLAST [16] analysis (an
unambiguous hit with e-value of ≥10e−45). For verification and elimination of false positives,
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library plasmids were purified from yeast [17], amplified in Escherichia coli (genelute plasmid
mini-prep kit, sigma-aldrich, st. Louis, mo), and transformed into clontech matchmaker gold
yeast with either the Pbp1 bait plasmid (pJG1386) or the empty bait plasmid (pJG424). Colonies
arising on the SD-leu-trp transformation plates were then streaked onto SD-leu-trp-his-ade in
duplicate and allowed to grow for 3–5 d to test for Pbp1 dependence. The strength of growth was
determined by comparing growth of yeast on SD-leu-trp-his-ade plates, which is an indication of
the interaction strength (s, strong; m, medium; w, weak) (Figure 5.2).
5.3.6 Mass spectrometry
Full length Pbp1 (pJG1560) into HIS expression under the GAL1-10 promoter was made
by PCR amplifying Pbp1 with primers JG2916/2917 and cloning into the EcoRI/XhoI sites of
pJG859. The protein was purified, run on 10% SDS PAGE, stained with coommassie blue and
78 kDa protein purified with it was cut from protein gel using a sterile razorblade. The gel slice
was flash frozen at -80°C and sent to Majid Ghassemian, Department of Chemistry and
Biochemistry, University of California, San Diego, for phosphosite mapping.
5.3.7 PTC6 colocalization
Ptc6-GFP fusion yeast (JGY1603) was obtained from the O’shea collection
(ThermoFisher). Pbp1-RFP was transformed into JGY1603 to monitor colocalization of Pbp1
and Ptc6 to stress granules. Overnight samples were grown according to Demille et al. Briefly,
samples were grown in in SD-Ura medium overnight, pelleted and re-suspended in SGal-Ura to
induce expression of Pab1-RFP. Cultures were then grown 4 days, pelleted, washed, and resuspended in synthetic complete medium. Cultures were grown for an additional hour at 30°C.
Confocal fluorescent imaging stacks were acquired using an Olympus FV1000 confocal
microscope. A 60x lens was used with 10x zoom, 0.4 µm step size and resolution of 640x640
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pixels/frame for image acquisition. Deconvolution of images was performed using cellSens
(Olympus).
5.3.8 Mitophagy assay
Mitophagy assays were performed via the method outlined by Kanki et al. Briefly,
Om54-GFP DNA fragment was amplified from JGY1586 using JG4522 and JG4523. PCR
product was transformed into JGY43, JGY1122, JGY 1598, and JGY1244 using standard yeast
transformation methods. Correct integration was verified through fluorescence microscopy and
PCR analysis of the genomic DNA (JG4524/JG4525).
Single colonies were picked and used to inncoluate 5mL YPD and grown to mid-log
phase. Aliquots equal to OD~0.1 were collected for t=0, and the remaining cultures were
centrifuged and re-suspended in a flask containing YPL (OD ~0.2). Cultures were grown shaking
for 48 hours at 30°C, then aliquots equal to OD~0.1 were collected by centrifugation, resuspended in 50 µL of 10% TCA, incubated on ice for 10 minutes, and frozen until ready to be
broken open for SDS-Page. To break open, samples were thawed on ice and pelleted by
centrifugation at 21,000xg for 10 minutes. Supernatant was removed, pellets were washed twice
with 500 uL of cold acetone, and air dried. Samples were then re-suspended in 50 µL sample
buffer (150 mM Tris-HCl, pH 8.8, 6% SDS, 25% glycerol, 6 mM EDTA, 0.5% 2mercaptoethanol, and 0.05% bromophenol blue), disrupted by vortex with an equal amount of
glass beads for 3 minutes, and incubated at 100°C for 3 minutes.
5 µL of sample was loaded on a 12% polyacrylamide gel and resolved. Transfer was
completed using the TurboBlot program, 2 midi-gel mixed MW program, transferring onto a
nitrocellulose membrane. Membranes were blocked with 5% milk, then probed with anti-GFP
antibody (1:5000 TBST) at 4°C overnight, washed, then probed with HRP-conjugated anti134

mouse (1:10,000 TBS) for 1 hour at room temperature. Membranes were developed using the
WesternBright ECL HRP substrate (Advansta Inc., San Jose, CA, USA, catalog number K12045-D50) according to the manufacturer’s protocol. Membranes were then striped and probed
with anti-UGP1 to ensure equal loading between samples. Bands were quantified using the
ImageJ software version 1.50i (National Institute of Health, Bethesda, MD, USA).
5.3.9 Plate respiration assays
Cultures were grown overnight in YPAD growth media. 1:10-fold serial dilutions were
performed and 5 µL of each dilution tube was plated onto both SD-Ura and S-Gly-EtOH-Ura.
Plates were grown for 2-3 days at 30°C and images acquired.
5.4 Results
5.4.1 A screen for Pbp1 binding partners reveals novel putative functions
Human ataxin-2 plays a pivotal role in the development of human ataxias (3, 4, 18), yet
little is known about its function. A sensitive and reliable approach for identifying protein
binding partners is copurification followed by quantitative mass spectrometry (MS). Full-length
Pbp1 fused with a HIS epitope was affinity purified in triplicate, and samples were subjected to
quantitative liquid chromatography (LC)–tandem MS. Twenty-five putative binding partners
were identified for Pbp1 when compared with the empty HIS vector control also performed in
triplicate (Table 5.4). Copurification screens retrieved both expected and novel binding partners.
The copurification screen retrieved several proteins known to regulate Pbp1.
To further elucidate the function of this proteins, the yeast two-hybrid (Y2H) approach was
employed utilizing the yeast ataxin-2 homolog, Pbp1 as bait. A truncation of Pbp1 (ΔN419Pbp1)
was previously identified as active in Y2H screens and was screen against two yeast genomic
libraries (pJG428, and pJG429) [13] and two cDNA libraries (JGY1098 and JGY1074) [14].
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From ∼10 million transformants and mated yeast screened, seven Pbp1 binding partners were
identified (Table 5.5).

Table 5.4 Pbp1 binding partners identified by mass spectrometry
Human
Gene
Name description
Homolog
RNA Processing
IMP
IMP4
SSD1
N/A
Protein Transporter
TRS31

TRAPPC5

VPS29

VPS29

SSY1

N/A

SEC24
SEC24
TIM9
TIMM9
Cell Cycle

snoRNA-binding rRNA-processing protein
mRNA-binding translational repressor
Core component of transport protein particle (TRAPP)
complexes I-III
Vacuolar Protein Sorting
Component of the SPS plasma membrane amino acid
sensor system
COPII vesicle coat component
Mitochondrial inner membrane translocase

Localization

# of times
retrieved

N
N/C

2
1

C/G

1

ES/ V

1

PM

1

ER/G/C
M

1
1

CDC50

TMEM30

Cell division control protein 50

ES

1

MCM5
APC9
BNR1
CYR1
CDC3
SPR28

MCM5
N/A
FMNL1
PHLPP2
SEPT7
SEPT1

MiniChromosome maintenance protein 5
Anaphase Promoting Complex subunit 9
BNI1-related protein 1
Adenylate Cyclase & magnesium ion binding
component of 10 nm filaments of mother-bud neck
Septin-related protein expressed during sporulation

N
CD
CD
CD
CD
W/ S

1
1
1
1
1
1

FUN19
Other

TADA2A

SWIRM domain-containing protein

C

1

INA22
RAD33
APE3
FRE7

N/A
N/A
ERMP1
CYBB

Inner membrane assembly complex subunit 22
Nucleotide excision repair
Aminopeptidase Y
Ferric reductase PM

M
N
V
PM

2
1
1
1

NIT1
N/A
Nitrilase
ZRT2
N/A
low-affinity Zn(2+) transporter
MOT3
N/A
Involved in cellular adjustment to osmotic stress
Protein of Unknown function

PM
N/C

1
1
1

YHR131
CP

N/A

Protein of Unknown function

C

1

FRT1

N/A

Tail-anchored ER membrane protein of unknown
function

ER

1

PM/ER/
1
G
For localization: C, cytoplasm; M, mitochondrion; N, nucleus; ER, endoplasmic reticulum; PM, plasma
membrane; W, cell wall; G, golgi; SG, stress granule; S, meiotic spindle; ES, Endosome; CD, cell division
sites.
SYG1

XPR1

Signal Transduction
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Table 5.5 Pbp1 binding partners identified by yeast two-hybrid
Human
#
Description
Loc.
Gene
Homolog
hits

Pray
library

Construct
(total aa)

Growth
strength

RNA Processing
MUM2

ERC2

PAT1

SLC36A1

PKH1

Pdpk1

Hypoth
etical
Protein
(SGDI
D:S00
00034
82)
Other Functions
YEN1

GEN1

mRNA methylation
Deadenylationdependent mRNAdecapping factor
Cytoplasmic mRNA
processing body
assembly
Putative RNA binding
protein

Response to DNA
damage stimulus

N/C

3

cDNA

aa170 to
aa298 (aa366)

W

N/C

1

Gen

aa2 to aa192
(aa796)

S

C/V

1

cDNA

aa649 to
aa741 (aa766)

M

C/SG

2

Gen

aa509 to
aa718
(aa718)

W

N/C

2

Gen

aa504 to
aa759
(aa759)

W

mitochondrion
aa1 to aa120
degradation,
M
1
Gen
S
(aa442)
macroautophagy
misfolded protein
ER/
aa407 to
SEC61 SEC61A2
1
Gen
M
transport
MEM
aa480 (aa480)
C corresponds to cytoplasm, MEM to membrane, M to mitochondrion, N to nucleus, ER to endoplasmic
reticulum, V to vacuole and SG to stress granule. S, strong; M, medium; W, weak
PTC6

PPM1K

Advantages of the Y2H approach include the identification of direct protein–protein
interactions and sensitivity due to transcriptional amplification of an interaction [14]. However,
the yeast two-hybrid can also yield false positives that allow growth independent of the bait. To
minimize false positives, the Y2HGold strain was used, which harbors four different reporters
control (Clontech Matchmaker Gold Yeast Two-hybrid System) [13], and each of these binding
partners was verified by purifying the prey plasmid from yeast and retransforming into naive
Y2HGold along with the ΔN419Pbp1 bait or an empty bait plasmid. The strength of growth is
an indication of strength (Figure 5.2). The Y2H screen retrieved all novel binding partners
including four involved in RNA processing. Although a role for Pbp1 in mRNA regulation was
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known, these direct binding partners may reveal a more precise function through future study.
The Y2H screen also revealed three additional proteins (YEN1, PTC6 and SEC61) all involved
in stress response, specifically DNA damage response, mitophagy, and the misfolded protein
response respectively.

Figure 5.2 Dependency assay and growth comparison. For verification and elimination of false positives,
library plasmids were purified and transformed into Clontech Matchmaker Gold yeast with either the bait
plasmid (pJG1386) or the empty bait plasmid (pJG424). Colonies arising on the SD-Leu-Trp
transformation plates were then streaked to SD-Leu-Trp-His-Ade in duplicate and allow growing for 3–5 d
to test for Pbp1 dependence. The strength of growth was determined by comparing growth of yeast on
SD-Leu-Trp-His-Ade plates, which is an indication of the interaction strength. (a) SEC61: Medium growth;
Hypothetical Protein: Weak growth. (b) PAT1 and PTC6: Strong Growth.

5.4.2 Pbp1 sequesters Ptc6 at stress granules
Due to the metabolic alterations seen in ALS patients, as well as the role of mitophagy in
ALS patients [19], Ptc6 was chosen for further study. Previous studies have revealed localization
of Pbp1 to stress granules along with the Pbp1-dependent sequestration TORC1 at stress
granules. To determine if Pbp1 is regulating Ptc6 activity via sequestration to stress granules,
confocal microscopy was performed using Ptc6-GFP and Pbp1-RFP. Stress granule formation
was induced by glucose deprivation. As shown in figure 5.3, Pbp1 and Ptc6 were shown to
colocalize within the cell to cytoplasmic foci. This suggests that Pbp1 is sequestering Ptc6 to
stress granules when the cell is under carbon starvation stress.
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Figure 5.3 Colocalization of Pbp1 and Ptc6. Ptc6-GFP fusion yeast (ThermoFisher) was transformed with
Pbp1-RFP (JG1669), grown under glucose deprivation, and imaged using an Olympus Fluoview confocal
microscope.

5.4.3 Pbp1-deficient yeast exhibit increase mitophagy and mitophagy is restored in
Pbp1/Ptc6-deficient yeast
Mitophagy is the process of clearing damaged mitochondria from the cell. It is thought
that improper mitophagy can lead to the accumulation of dysfunctional or damaged
mitochondria, contributing to neurodegeneration in ALS [19]. Ptc6 was chosen for further
characterization as an interacting partner of Pbp1 because Ptc6 has been reported to be essential
for mitophagy. Mitophagy assays were used to test our hypothesis that Pbp1 is inactivating Ptc6
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by sequestration assays, just as it inactivates TORC1. If Pbp1 is absent from the cell, it is
potentially not sequestering Ptc6 to stress granules allowing for increased mitophagy.
Mitophagy was induced through 48 hours growth in YPL and mitophagy was quantified
by the amount of degraded OM45-GFP, measured through western blot. ATG1 was included as a
control, as it should block mitophagy pathways. The level of mitophagy seen in Ptc6 matched
what has been reported in previous studies, with mitophagy being lowered in this strain (Figure
5.4). Pbp1-deficient yeast (pbp1) showed significantly elevated levels of mitophagy, suggesting a
novel role of Pbp1 in regulating mitophagy within the cell. In addition, pbp1ptc6 yeast showed
mitophagy levels similar to wild-type consistent with elevated levels pbp1 yeast due to increased
activity of Ptc6. The return to wild type levels was, however, unexpected as Ptc6 has been
reported as an essential gene necessary for mitophagy and suggests upregulation of unknown
pathways in the Ppb1 knockout. The remaining strains tested revealed no significant changes.
One-way ANOVA was performed using JMP Pro14 (version 14.0) software (SAS Institute,
Cary, NC, USA) with Tukey’s post-hoc test.

Figure 5.4 Pbp1 yeast display increased levels of mitophagy . Mitophagy assays were conducted using
the OM45-GFP processing assay developed by Kanki et al. Mitophagy was induced through growth in
YPL and the amount of degraded GFP was measured as a marker for mitophagy. Bands were quantified
using ImageJ. Significance was determined by one-way ANOVA and Tukey’s post-hoc test. n=2.
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5.4.4 PTC6-deficient yeast exhibit mitochondrial alterations
Due to the significant increase in mitophagy in Pbp1-deficient yeast and the significant
decrease in mitophagy in Ptc6-defiicent yeast, mitochondria health was measured in each of the
strains tested for the mitophagy assay. First, mitochondria content was quantified using flow
cytometry. Mitochondria were tagged with OM45-GFP and endoplasmic reticulum was tagged
with RFP. Endoplasmic reticulum was used as a cellular control. Consistent with a defect in
mitophagy, our results show that PTC6-deficient yeast contain significantly more mitochondria
(Figure 5.5A). However, PTC6/Pbp1-deficient yeast show levels similar to WT. One-way
ANOVA was performed using JMP Pro14 (version 14.0) software (SAS Institute, Cary, NC,
USA) with Tukey’s post-hoc test.
This change in mitochondria content suggested that a change in respiration may also be
seen due to the elevated mitochondrial content. The ability of each strain to grow on respiratory
carbon source was utilized to determine if any noticeable respiratory differences could be
detected. Each strain was grown up overnight and 1:10-fold serial dilution were performed and
plated 1:100-fold serial dilutions were performed from the overnight and plated onto both
glucose (a fermentative carbon source) and glycerol/ethanol (a respiratory carbon source).
Following two days of growth, it was revealed that Ptc6-deficient yeast showed increased colony
mass (Figure 5.5B), consistent with the increased mitochondria we observed (Figure 3A).
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A.

B.

Figure 5.5 Evidence for Ptc6 regulation of respiration. (A) Mitochondria was quantified using flow
cytometry. OM45-GFP was used as a marker for mitochondrial content and the ER was quantified using
Sec63-RFP, a protein in the ER. The ER was included as a control of overall cellular content. (B) Spot
dilutions revealed increased respiration in Ptc6 yeast. Together, these results suggest the elevated
mitochondrial content is contributing to elevated respiration.

5.5 Discussion
There are approximately 16,000 Americans living with ALS at any given moment. With
a typical survival time of only 2-5 years, it can be a grim diagnosis with few treatment options.
Fortunately, advances in technology have allowed for a more in-depth understanding of the
pathways involved in the disease and subsequent potential drug targets [20]. Recently, ataxin 2
has been identified as a promising therapeutic target for ALS. It has been shown that
intermediate-length polyglutamine expansions in the ataxin 2 gene increases the risk of ALS.
Furthermore, it has been shown that by lowering the levels of ataxin 2 it is possible to mitigate
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disease caused by TDP-43 proteinopathy in yeast, flies, and mice. As such, the regulation of
ataxin 2 is a promising target for ALS treatment. PAS kinase has been identified as a protein
kinase that regulates ataxin 2 activity. This is an extremely fortunate discovery as PAS kinase
inhibitors have already been identified and are starting to be developed, making regulation of
ataxin 2 through PAS kinase a very feasible task. PAS kinase is responsible for phosphorylating
and activating ataxin-2, causing sequestration of various proteins to stress granules. As such,
development of a PAS kinase inhibitor would result in a decreased ataxin-2 activity and resulting
sequestration of proteins to stress granules. This study is focused on identifying proteins that
interact with ataxin-2 through a study of its binding partners in yeast.
We performed a large-scale yeast interactome to identify Pbp1 binding partners through
yeast-two hybrid and mass spectrometry. We identified 32 novel putative binding partners (7
from yeast two-hybrid and 25 from mass spectrometry). This has largely expanded the role of
Pbp1 in yeast, which includes 6 proteins that are involved in RNA processing, 5 proteins
involved in protein transportation, 8 cell cycle proteins, and 13 proteins with other unknown
functions. In addition, 21 of the 32 identified binding partners have a homolog, suggested a
possible conserved function between yeast and man.
Through the yeast two-hybrid assay we identified Ptc6 as a novel interacting partner of
Pbp1. Ptc6 (also referred to as Aup1 or PPP2 in yeast) is a serine/threonine phosphatase that is
localized to the mitochondria. Ptc6 was previously reported to be necessary for efficient
mitophagy and cell survival in yeast [21]. This role in mitophagy was validated herein through
the OM45-GFP processing assay, as PTC6 yeast demonstrated decreased levels of mitophagy
(Figure 5.4). Interestingly, pbp1 yeast exhibited significantly increased levels of mitophagy. This
result combined with our colocalization assays creates a model for how Pbp1 is interacting with
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Ptc6. We hypothesize that when Pbp1 is activated, it sequesters Ptc6 to the stress granule,
effectively deactivating Ptc6 function in the cell and decreasing mitophagy pathways (Figure
5.6). When Pbp1 is absent from the cell, Ptc6 is not sequestered to the stress granules, resulting
in an increase in Ptc6 function and increased mitophagy. This result is especially interesting
when looking at the context of ALS. In ALS, mitophagy pathways are often blocked, allowing
for the accumulation of damaged mitochondria in the cell and contributing to neurodegeneration
[19]. Elevated mitophagy in Pbp1 yeast suggests yet another benefit of targeting Pbp1/ataxin-2
for ALS therapy, as lowering levels of Pbp1/ataxin-2 will result in increased mitophagy and
decreased accumulation of damaged mitochondria. The regulation of mitophagy in ALS may be
through the mammalian Ptc6 homolog PPM1K.
A.

B.

Figure 5.6 A model of Pbp1/ataxin-2 sequestration of Ptc6 to stress granules. (a) Pbp1 activation by PAS
kinase results in sequestration of both Pbp1 and Ptc6, thus decreasing the function of Pbp1. (b) When
Pbp1 is absent from the cell, Ptc6 is no longer sequestered to stress granules, remaining functional and
possibly contributing to the increased mitophagy seen in Pbp1 yeast.

The defect of mitophagy in ptc6 yeast prompted a deeper understanding of the
mitochondria in these yeast strains. Flow cytometry assays revealed elevated mitochondria in
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PTC6 yeast. This is supported by the mitophagy assays, as an inability to perform mitophagy
would result in elevated levels of mitochondria in the cell. Furthermore, PTC6 yeast appear to
have increased respiration as shown by plate assay. As such, further characterization of the
mitochondria is needed to determine if the yeast is accumulating damaged and dysfunctional
mitochondria in the cell. This includes viewing mitochondrial morphology via confocal
microscopy and measuring mitochondrial respiration via the Seahorse XF Cell Mito Stress Test.
In addition to the mitochondrial phenotypes seen in Ptc6 yeast, Ptc6 yeast has been shown to be
sensitive to rapamycin. This is very interesting because TORC1 is also sensitive to rapamycin. It
A.

B.

Figure 5.7 Possible models of Ptc6 dependent sequestration of TORC1 to stress granules . (a) Ptc6 is
required for TORC1 sequestration to stress granules. In its absence, TORC1 is not sequestered to stress
granules. (b) Ptc6 is not required for TORC1 sequestration to stress granules.

is known that Pbp1 sequesters TORC1 to stress granules, but it is unknown how that happens. It
is possible that Pbp1 directly binds Ptc6 (as suggested by the yeast 2-hybrid assay, Table 3), and
that Pbp1 is working through Ptc6 to sequester TORC1 to stress granules. This would also
suggest that the Ptc6 sensitivity to rapamycin could in part be due to it sequestering TORC1 to
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stress granules. To test this theory, TORC1-GFP could be transformed into Ptc6 yeast with
Pabp1-RFP allowing for sequestration of TORC1 to stress granules to be monitored. If Ptc6 is
responsible for sequestration, then TORC1 will not colocalize with Pab1-RFP in the stress
granules (Figure 5.7A). If TORC1 does colocalize to the stress granules, it would suggest that
Pbp1 is regulating the Ptc6 and TORC1 pathways separately (Figure 5.7B).
Through the identification of these 32 novel interacting partners of Pbp1 and the
characterization of Ptc6, we have further solidified the importance of understand the role of
Pbp1/ataxin-2 in ALS. By understanding both its upstream and downstream pathways, it will
become more apparent how to best utilize it as a therapeutic target to help individuals with the
disease.
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CONCLUSIONS
Herein we characterized two novel substrates of PAS kinase, Cbf1 and Pbp1. First, we
identified a novel role of Cbf1 in cellular respiration. In the absence of PAS kinase, Cbf1 is not
inhibited by phosphorylation and shifts glucose towards respiration and away from lipogenesis.
We further studied this shift in a mouse model of PAS kinase deficiency on either a normal chow
diet or a high-fat high-sugar diet. We found that PAS kinase deficiency will shift glucose
towards respiration and away from lipogenesis, just as it did in our yeast model. This was shown
through respiration assays and through lipidomics analysis. These studies have deepened our
understanding of how PAS kinase is functioning in both yeast and mice.
Next, we provided further characterization of the function of Pbp1. Pbp1 has a human
homolog called ataxin-2. Mutations in ataxin-2 have been associated with amyotrophic lateral
sclerosis (ALS), and removal of ataxin-2 in an ALS mouse model significantly increases the
lifespan of the animal. ALS is a neurodegenerative disease, but it presents with many metabolic
abnormalities that can be affected by diet, metabolic health, and sex. These changes were
reviewed in-depth within this dissertation.
We furthered the understanding of Pbp1 function by identifying 32 interacting partners of
Pbp1. We further characterized one of these partners identified by yeast-two hybrid assay, Ptc6.
We provided evidence of Pbp1 regulation of Ptc6 by sequestration to stress granules. Initial
studies show Pbp1 and Ptc6 regulation of mitophagy, and Ptc6 deficiency affecting
mitochondrial content and function. These studies have provided insight into the interaction of
Pbp1 and Ptc6 while also opening up exciting new questions about how Pbp1 and Ptc6 are
involved in mitochondrial function, from respiration to mitophagy. The following experiments
are suggested in order to answer these questions in the future:
150

Question 1: Is Pbp1 responsible for Ptc6 sequestration to stress granules
Experiment 1.1 Tag Ptc6 with GFP and Pabp1 (a known stress granule marker) with RFP.
Transform these into Pbp1-deficeint yeast and view via confocal microscopy using the
steps outlined in chapter 5. If Pbp1 is responsible for Ptc6 sequestration to stress
granules, the in its absence we expect that Ptc6 will not be localized to stress granules.
Question 2. Is Ptc6 required for TORC1 sequestration to stress granules?
Experiment 2.1: Growth Assays to determine if TORC1 can be sequestered to stress
granules in the absence of Ptc6. Spot wild-type, Ptc6-deficient, and Ptc6-deficient with
Pbp1 overexpressing on a plasmid to caffeine plates. If the yeast can grow on caffeine in
the absence of Ptc6, it suggests that Ptc6 is essential for TORC1 sequestration to stress
granules.
Experiment 2.2 Colocalization analysis to determine of TORC1 can be sequestered to
stress granules in the absence of Ptc6. Tag TORC1 with GFP in a Ptc6 knockout yeast
strain. Follow the procedure outlined for colocalization analysis. Localization of TORC1
to the stress granules in the absence of Ptc6 suggests that Ptc6 is not responsible for the
sequestration of TORC1 to stress granules.
Question 3: Do Ptc6-deficient yeast collect damaged mitochondria
Experiment 3.1 Our plate assays suggest that Ptc6-deficient yeast have increased
respiration because of the increased colony size. We suggest performing respiration
assays on the Seahorse XF Analyzer. We suggest performing this experiment in the
strains shown in the spot dilutions, with the addition of the Pbp1/Ptc6 double knockout.
This will help determine if the increased colony size is due to increased respiration.
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Experiment 3.2 Our flow cytometry assays show Ptc6 deficient yeast have increased
mitochondria. However, because Ptc6-deficient yeast show decreased mitophagy it is
possible that damaged mitochondria is being collected. We suggest tagging the
mitochondria with an RFP tag to determine morphological changes via confocal
microscopy.
Ultimately, these experiments will shed light into how PAS kinase, Pbp1, and Ptc6 are
interacting to regulate mitophagy and overall mitochondrial health within the cell. This pathway,
along with the pathways mentioned throughout this dissertation, are promising targets for future
drug development for metabolic and neurodegenerative disease. Further understanding of these
pathways will provide for the most safe and effective therapies for patients.
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